0001213900-26-086751 | 10-K/A | XBRL Viewer

189

690

(188)

(73)

(3)

(96)

(207)

Stock based compensation

1,444

3,077

3,429

3,724

281

505

941

1,387

(227)

^[1]

422

(4,218)

Accrued expenses

(88)

^[1]

1,280

(82)

Purchase of property and equipment

(2,358)

^[1]

(4,937)

^[1]

(5,409)

^[1]

(8,911)

(4,941)

(138)

(386)

(4,839)

(5,144)

(844)

Purchase of long-term investments

(84)

^[1]

(590)

(5,471)

(142)

^[1]

(102)

730

Payment of issuance cost of ordinary shares

(440)

^[1]

(15,335)

^[1]

(41,741)

^[1]

(56,183)

(22,851)

(1,180)

Proceeds from Warrant Exercises

18,038

18,909

Contributions from Non-controlling Interests

^[1]

Proceeds from issuance of ordinary shares

8,063

18,038

48,650

219,808

30,182

Allowance for credit loss

8,059

^[1]

16,832

^[1]

65,477

^[1]

236,102

41,925

^[1]

(94)

Schedule of Restated Audited Consolidated Statement of Cash Flows [Line Items]

Net loss

(3,548)

^[1]

(8,126)

^[1]

(12,238)

^[1]

(15,754)

(8,140)

Change in fair value of warrant liability

(248)

(343)

(334)

(232)

(326)

Stock based compensation

513

730

1,635

2,319

(321)

^[1]

421

Accrued expenses

(91)

^[1]

Purchase of property and equipment

(3,578)

^[1]

(8,076)

^[1]

(11,197)

^[1]

(9,043)

(5,060)

(78)

(116)

(4,509)

(5,009)

(725)

Purchase of long-term investments

(100)

^[1]

(591)

(5,470)

^[1]

(247)

Payment of issuance cost of ordinary shares

(380)

^[1]

(15,130)

^[1]

(41,532)

^[1]

(47,996)

(22,731)

Proceeds from Warrant Exercises

Contributions from Non-controlling Interests

^[1]

(21)

Proceeds from issuance of ordinary shares

9,244

19,792

71,087

Allowance for credit loss

9,219

^[1]

19,766

^[1]

71,056

^[1]

41,923

^[1]

Schedule of Restated Audited Consolidated Statement of Cash Flows [Line Items]

Net loss

(26,017)

^[1]

(22,011)

^[1]

(19,591)

^[1]

(33,428)

6,772

Change in fair value of warrant liability

25,965

21,837

22,123

189

270

331

136

119

Stock based compensation

1,444

3,077

3,429

(232)

(225)

(694)

(932)

^[1]

Accrued expenses

^[1]

(120)

Purchase of property and equipment

1,220

^[1]

3,139

^[1]

5,788

^[1]

132

119

(60)

(270)

(330)

(135)

(119)

Purchase of long-term investments

^[1]

(1)

^[1]

105

Payment of issuance cost of ordinary shares

(60)

^[1]

(205)

^[1]

(209)

^[1]

$ (8,187)

(120)

(1,180)

Proceeds from Warrant Exercises

18,038

Contributions from Non-controlling Interests

^[1]

Proceeds from issuance of ordinary shares

(1,181)

(1,754)

(22,437)

Allowance for credit loss

$ (1,160)

^[1]

(2,934)

^[1]

$ (5,579)

^[1]

$ 2

^[1]

$ (94)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Nature of Business

12 Months Ended

Sep. 30, 2025

Nature of Business [Abstract]

Nature of Business

NOTE 1: Nature of Business

Description of Business

Richtech Robotics Inc. (“we”, “us”, “our” or “Richtech”), is a C-Corporation registered in Nevada. Richtech was originally established as Richtech Creative Displays, LLC in Nevada on July 19, 2016, and converted to a Nevada corporation on June 22, 2022. We completed our initial public offering on November 21, 2023, and shares of our Class B common stock began trading on the Nasdaq Capital Market on November 17, 2023 under the symbol “RR.”

We are a robotics and artificial intelligence (“AI”) technology company focused on developing advanced embodied AI systems that aims to improve the efficiency and productivity of U.S. businesses. Richtech trains proprietary artificial intelligence models on in-house data to operate advanced robotic systems in the real world. We design, engineer, manufacture, and deploy next generation embodied AI systems to serve a wide range of industries—including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. Our robots are designed to be user friendly, reliable, and highly customizable, with the goal of driving tangible profit and loss (“P&L”) improvements for our customers.

Our mission is to accelerate the advancement of embodied AI in the United States. We aim to become a robotics “Super-Operator”—i.e. a company operating over one hundred thousand intelligent robots connected through a unified, data-rich AI ecosystem. These robots will perform a wide range of tasks across commercial and industrial environments, from scrubbing floors and packaging deliveries to supporting medical staff in hospitals and staffing factory production lines.

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating Activities:
Consolidated net loss	$ (49,182)	$ (1,368)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,387	98
Change in fair value of derivative instruments	34,172	(7,587)
Issuance costs related to warrants	189	690
Amortization of notes payable discount		120
Stock based compensation	3,724
Accounts receivable	(422)	4,218
Inventory	(96)	(207)
Prepaid expenses and other current assets	(396)	(16)
Right-of-use asset	(225)	(191)
Accounts payable	247	(976)
Deferred revenue	248
Tax payable	50	(456)
Accrued expenses and other payable	1,280	(82)
Deferred income taxes	(108)	626
Change in operating lease liabilities	221	190
Net cash used in operating activities	(8,911)	(4,941)
Cash flows from investing activities:
Purchase of PPE	(5,144)	(844)
Purchase of intangible assets	(590)	(5,471)
Purchase of short-term investments	(50,028)	(15,940)
Purchase of long-term investments	102	(730)
Notes receivable	(523)
Cash used for lending to related parties		134
Net cash used in investing activities	(56,183)	(22,851)
Cash flows from financing activities:
Payment of loans received from third parties	(53)	(3,792)
Contributions from Non-controlling Interests	65
Payment of issuance cost of ordinary shares	(2,643)
Proceeds from warrants exercise	18,909
Loans received from third parties	16	3,102
Loan settlement		3,385
Payment of related party debt		(238)
Proceeds from issuance of ordinary shares	219,808	30,182
Proceeds from stockholder capital injection		9,286
Net Cash provided by financing activities	236,102	41,925
Net change in cash and cash equivalents	171,008	14,133
Cash, cash equivalents and restricted cash at beginning of the period	14,566	433
Cash, cash equivalents and restricted cash at end of the period	185,574	14,566
Supplemental noncash disclosures:
Intangible assets acquired in exchange for common shares	$ 3,702	$ 2,217

Fair Value of Financial Instruments - Schedule of Cash, Cash Equivalents and Investments Classified by Security Type (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Schedule of Cash, Cash Equivalents and Investments Classified by Security Type [Line Items]
Adjusted Cost	$ 251,544	$ 30,506
Gross Unrealized Gains	393
Gross Unrealized Losses
Fair Value	251,937	30,506
Cash and Cash Equivalents	185,574	14,566
Short-Term Investments	66,363	15,940
Cash [Member]
Schedule of Cash, Cash Equivalents and Investments Classified by Security Type [Line Items]
Adjusted Cost	76,441	14,566
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	76,441	14,566
Cash and Cash Equivalents	76,441	14,566
Short-Term Investments
U.S. government securities [Member]
Schedule of Cash, Cash Equivalents and Investments Classified by Security Type [Line Items]
Adjusted Cost	80,915
Gross Unrealized Gains	393
Gross Unrealized Losses
Fair Value	81,308
Cash and Cash Equivalents	62,917
Short-Term Investments	18,391
Certificates of deposit and time deposits [Member]
Schedule of Cash, Cash Equivalents and Investments Classified by Security Type [Line Items]
Adjusted Cost	48,656	15,940
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	48,656	15,940
Cash and Cash Equivalents	684
Short-Term Investments	47,972	$ 15,940
Money market funds [Member]
Schedule of Cash, Cash Equivalents and Investments Classified by Security Type [Line Items]
Adjusted Cost	45,532
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	45,532
Cash and Cash Equivalents	45,532
Short-Term Investments

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 03, 2024	Apr. 22, 2024	Feb. 15, 2024	Dec. 22, 2023	Nov. 21, 2023	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2025	Jun. 30, 2025	Sep. 30, 2025	Sep. 30, 2024
Stockholders’ Equity [Line Items]
Warrants expire term	5 years
Other income (loss)						$ (286)	$ 4,128	$ (25,965)	$ (21,837)	$ (22,123)	$ (34,172)	$ 7,587
Standby Equity Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Other income (loss)												$ 2,305
YA II PN, Ltd. [Member] \| Standby Equity Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Aggregate shares through at-the-market (“ATM”) offerings		259,350
Commitment shares		259,350
Class A Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock shares issued											39,934,846	39,934,846
Common stock shares outstanding											39,934,846	39,934,846
Aggregated common share issued
Class A Common Stock [Member] \| Common Stock [Member]
Stockholders’ Equity [Line Items]
Stockholders upon the conversion of stock												(4,419,000)
Class B Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock shares issued											154,656,592	53,795,254
Common stock shares outstanding											154,656,592	53,795,254
Aggregated common share issued											100,861,338
Number of trading days			5 days
Class B Common Stock [Member] \| Employees and Directors [Member]
Stockholders’ Equity [Line Items]
Stock compensation to employees and directors												46,957
Class B Common Stock [Member] \| Common Stock [Member]
Stockholders’ Equity [Line Items]
Stock issued for legal and professional services											1,793,095
Stock compensation to employees and directors											1,023,040	51,890
Stockholders upon the conversion of stock												4,419,000
Aggregate shares through at-the-market (“ATM”) offerings											79,241,455	22,343,961
Stock issued for technology development services											5,788,849	4,730,726
Common stock exercise of investor warrants											13,014,899
Commitment shares											79,241,455	22,343,961
Class B Common Stock [Member] \| 2023 Stock Option Plan [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued											8,721,735	4,829,573
Stock issued for legal and professional services												4,730,726
Stock compensation to employees and directors											861,904
Stock issued for technology development services											5,788,849
Class B Common Stock [Member] \| Standby Equity Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued												8,776,211
Company purchase price (in Dollars)			$ 50,000
Percentage of lowest volume weighted average price			96.00%
Number of trading days			3 days
Class B Common Stock [Member] \| Securities Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued	13,242,963
Class B Common Stock [Member] \| YA II PN, Ltd. [Member] \| Standby Equity Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Percentage of daily trading volume			100.00%
Initial Public Offering [Member] \| Class B Common Stock [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued					2,100,000
Common stock issued price per share (in Dollars per share)					$ 5
Underwriters Over Allotment Option [Member] \| Class B Common Stock [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued				42,563
Common stock issued price per share (in Dollars per share)				$ 5
Pre-funded Warrants [Member] \| Class B Common Stock [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued												2,312,594
Instrument Exercise Price												$ 0.00001
Pre-funded Warrants [Member] \| Class B Common Stock [Member] \| Securities Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued	2,312,594
Instrument Exercise Price	$ 0.00001
Common Warrants [Member] \| Securities Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Instrument Exercise Price	$ 1.35
Common Warrants [Member] \| Class B Common Stock [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued												0
Instrument Exercise Price												$ 1.35
Common Warrants [Member] \| Class B Common Stock [Member] \| Securities Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Aggregated common share issued	15,555,557
Common stock issued price per share (in Dollars per share)	$ 1.35
ATM Program [Member]
Stockholders’ Equity [Line Items]
Aggregate shares through at-the-market (“ATM”) offerings											79,241,455
Commitment shares											79,241,455

Summary of Significant Accounting Policies (Details) $ in Thousands	12 Months Ended
	Sep. 30, 2025 USD ($) segment shares	Sep. 30, 2024 USD ($)
Summary of Significant Accounting Policies [Line Items]
Operating segment \| segment	1
Allowance for credit losses	$ 139	$ 197
Depreciation expenses	192	31
Remaining performance obligations	1,376
Expected to recognized twelve months	704
Expected to recognized twenty four months	425
Expected to recognized after twenty four months	247
Contract liabilities	$ 248
Leases terms	12 months
Class A Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Capital stock authorized (in Shares) \| shares	100,000,000
Common stock vote	ten
Class B Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Common stock vote	one
Conversion of common stock (in Shares) \| shares	1
Minimum [Member] \| Leasehold Improvements [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of equipment	2 years
Maximum [Member] \| Leasehold Improvements [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of equipment	6 years
Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Capital stock authorized (in Shares) \| shares	300,000,000
Common Stock [Member] \| Class B Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Share issued of services (in Shares) \| shares	1,793,095
Preferred Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Share issued of services (in Shares) \| shares	10,000,000
2023 Stock Option Plan [Member] \| Class B Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Share issued of services (in Shares) \| shares	200,000,000

Intangible Asset, net

12 Months Ended

Sep. 30, 2025

Intangible Asset, Net [Abstract]

Intangible Asset, net

NOTE 6: Intangible Asset, net

The Company’s intangible assets consist of multiple systems purchased for our robotic product. These assets are amortized using the straight-line method over their estimated useful life of 10 years.

Intangible Asset, as of September 30, 2025 and September 30, 2024 are as follows:

	Years Ended September 30,
	2025			2024
Intangible assets	$	11,978		$	7,688
Accumulated amortization		(1,263	)		(68	)
Intangible assets, net	$	10,715		$	7,620

Amortization expense was $2,150 and $67 for the years ended September 30, 2025 and 2024, respectively. The increase was primarily attributable to additional intangible assets acquired during the current fiscal year and to intangible assets that were acquired in the prior fiscal year and incurred their first full year of amortization in the current fiscal year.

Estimated amortization expense related to existing finite-lived intangible assets for each of the next five years is as follows:

Fiscal Year	Estimated Amortization Expense
FY2026	$	1,194
FY2027	$	1,194
FY2028	$	1,194
FY2029	$	1,194
FY2030	$	1,194
Total	$	5,970

The Company performs an impairment assessment on an annual basis. For the fiscal year ended September 30, 2025, the Company’s assessment concluded that no impairment indicators were identified, and no impairment loss was recognized.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Restatement of Previously Issued Quarterly Financial Statements (Tables)

12 Months Ended

Sep. 30, 2025

Restatement of Previously Issued Quarterly Financial Statements [Abstract]

Schedule of Restated Unaudited Consolidated Balance Sheet

Restated Unaudited Consolidated Balance Sheet – As of June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Inventory	$	1,482		$	(256	)		8	$	1,226
Total current assets		88,851			(256	)		*		88,595
Property and equipment, net		5,164			216			7		5,380
Intangible assets, net		11,532			(964	)		9,13		10,568
Total assets		107,329			(1,004	)		*		106,325
Warrant liability		-			7,406			2,3		7,406
Total current liabilities		739			7,406			*		8,145
Deferred income taxes		-			108			10		108
Total liabilities		1,378			7,514			*		8,892
Mezzanine equity		-			975			1		975
Additional paid-in capital		126,114			3,325			1,2,3,4,13		129,439
Retained earnings		(20,099	)		(12,818	)		*		(32,917	)
Total stockholders’ equity		105,951			(9,493	)		*		96,458
Total liabilities, mezzanine equity and stockholders’ equity	$	107,329		$	(1,004	)		*	$	106,325

Restated Unaudited Consolidated Balance Sheet – As of March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Inventory	$	1,491		$	(195	)		7,8	$	1,296
Total current assets		45,139			(195	)		*		44,944
Property and equipment, net		816			165			7		981
Intangible assets, net		9,384			1,481			9,13		10,865
Total assets		57,179			1,451			*		58,630
Warrant liability		-			7,120			2,3		7,120
Total current liabilities		596			7,120			*		7,716
Deferred income taxes		-			108			10		108
Total liabilities		1,320			7,228			*		8,548
Mezzanine equity		-			975			1		975
Additional paid-in capital		71,913			8,488			1,2,3,4,13		80,401
Retained earnings		(16,027	)		(15,240	)		*		(31,267	)
Total stockholders’ equity		55,859			(6,752	)		*		49,107
Total liabilities, mezzanine equity and stockholders’ equity	$	57,179		$	1,451			*	$	58,630

Restated Unaudited Consolidated Balance Sheet – As of December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Inventory	$	1,396		$	(180	)		7,8	$	1,216
Total current assets		39,458			(180	)		*		39,278
Property and equipment, net		802			158			7		960
Intangible assets, net		9,576			1,481			9,13		11,057
Total assets		51,424			1,459			*		52,883
Warrant liability		-			20,564			2,3		20,564
Total current liabilities		993			20,564			*		21,557
Deferred income taxes		-			108			10		108
Total liabilities		1,555			20,672			*		22,227
Mezzanine equity		-			786			1		786
Additional paid-in capital		61,366			(776	)		1,2,3,4,13		60,590
Retained earnings		(11,487	)		(19,224	)		*		(30,711	)
Total stockholders’ equity		49,869			(19,999	)		*		29,870
Total liabilities, mezzanine equity and stockholders’ equity	$	51,424		$	1,459			*	$	52,883

Schedule of Restated Consolidated Statement of Operations

Restated Consolidated Statement of Operations – Three Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	301		$	445			5,8	$	746
Gross profit		876			(445	)		*		431
General and administrative		4,562			(3,153	)		5,6,7,13		1,409
Total operating expenses		5,383			(3,153	)		*		2,230
Loss from operations		(4,507	)		2,707			*		(1,800	)
Other income (loss)		-			(286	)		2,3		(286	)
Total other expenses		404			(286	)		*		118
Loss before income tax expense		(4,103	)		2,422			*		(1,681	)
Income tax benefit/(expense)		-			(9	)		*		(9	)
Consolidated net loss		(4,103	)		2,413			*		(1,690	)
Net loss attributable to common stockholders	$	(4,063	)	$	2,413			*	$	(1,650	)
Basic and diluted net loss per share of common stock	$	(0.04	)						$	(0.01	)

Restated Consolidated Statement of Operations – Nine Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	878		$	1,113			5,8	$	1,991
Gross profit		2,723			(1,113	)		*		1,610
General and administrative		13,827			(3,647	)		5,6,7,13		10,180
Total operating expenses		16,067			(3,647	)		*		12,420
Loss from operations		(13,344	)		2,534			*		(10,810	)
Other income (loss)		-			(22,123	)		2,3		(22,123	)
Total other expenses		1,115			(22,123	)		*		(21,008	)
Loss before income tax expense		(12,229	)		(19,589	)		*		(31,818	)
Consolidated net loss		(12,238	)		(19,589	)		*		(31,827	)
Net loss attributable to common stockholders	$	(12,151	)	$	(19,598	)		*	$	(31,749	)
Basic and diluted net loss per share of common stock	$	(0.11	)						$	(0.29	)

Restated Consolidated Statement of Operations – Three Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	454		$	348			5,8	$	802
Gross profit		713			(348	)		*		365
General and administrative		4,962			(205	)		5,6,7,13		4,757
Total operating expenses		5,652			(205	)		*		5,447
Loss from operations		(4,939	)		(143	)		*		(5,082	)
Other income (loss)		-			4,128			2,3		4,128
Total other expenses		382			4,128			*		4,510
Loss before income tax expense		(4,557	)		3,985			*		(572	)
Consolidated net loss		(4,557	)		3,985			*		(572	)
Net loss attributable to common stockholders	$	(4,540	)	$	3,985			*	$	(555	)
Basic and diluted net loss per share of common stock	$	(0.04	)						$	(0.00	)

Restated Consolidated Statement of Operations – Six Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	577		$	668			5,8	$	1,245
Gross profit		1,847			(668	)		*		1,179
General and administrative		9,265			(494	)		5,6,7,13		8,771
Total operating expenses		10,684			(494	)		*		10,190
Loss from operations		(8,837	)		(174	)		*		(9,011	)
Other income (loss)		-			(21,837	)		2,3		(21,837	)
Total other expenses		711			(21,837	)		*		(21,126	)
Loss before income tax expense		(8,126	)		(22,011	)		*		(30,137	)
Consolidated net loss		(8,126	)		(22,011	)		*		(30,137	)
Net loss attributable to common stockholders	$	(8,088	)	$	(22,011	)		*	$	(30,099	)
Basic and diluted net loss per share of common stock	$	(0.08	)						$	(0.29	)

Restated Consolidated Statement of Operations – Three Months Ended December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	123		$	320			5,8	$	443
Gross profit		1,134			(320	)		*		814
General and administrative		4,303			(289	)		5,6,7,13		4,014
Total operating expenses		5,032			(289	)		*		4,743
Loss from operations		(3,898	)		(31	)		*		(3,929	)
Other income (loss)		-			(25,965	)		2		(25,965	)
Total other expenses		329			(25,965	)		*		(25,636	)
Loss before income tax expense		(3,569	)		(25,996	)		*		(29,565	)
Consolidated net loss		(3,569	)		(25,996	)		*		(29,565	)
Net loss attributable to common stockholders	$	(3,548	)	$	(25,996	)		*	$	(29,544	)
Basic and diluted net loss per share of common stock	$	(0.04	)						$	(0.31	)

Schedule of Restated Consolidated Statement of Equity

Restated Consolidated Statement of Equity – Nine Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	126,114		$	3,325			*	$	129,439
Additional paid-in capital, issuance of common shares for intangible asset acquisition		5,378			(1,677	)		13		3,701
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		16,858			21,656			2,3		38,514
Additional paid-in capital, shares issued to employees		1,380			(475	)		13		905
Additional paid-in capital, shares issued for services		4,080			(1,556	)		13		2,524
Retained earnings		(20,099	)		(12,818	)		*		(32,917	)
Net loss attributable to common stockholders		(12,151	)		(19,598	)		*		(31,749	)
Total stockholders’ equity	$	105,951		$	(9,493	)		*	$	96,458

Restated Consolidated Statement of Equity – Three Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	126,114		$	3,325			*	$	129,439
Additional paid-in capital, issuance of common shares for intangible asset acquisition		2,924			(2,924	)		13		-
Additional paid-in capital, shares issued to employees		-			212			13		212
Additional paid-in capital, shares issued for services		2,591			(2,451	)		13		140
Retained earnings		(20,099	)		(12,818	)		*		(32,917	)
Net loss attributable to common stockholders		(4,063	)		2,413			*		(1,650	)
Total stockholders’ equity	$	105,951		$	(9,493	)		*	$	96,458

Restated Consolidated Statement of Equity – Six Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	71,913		$	8,488			*	$	80,401
Additional paid-in capital, issuance of common shares for intangible asset acquisition		2,454			1,247			13		3,701
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		16,858			21,656			2,3		38,514
Additional paid-in capital, shares issued to employees		867			(175	)		13		692
Additional paid-in capital, transfer to ESOP trust		513			(513	)		13		0
Additional paid-in capital, shares issued for services		1,175			1210			13		2,385
Retained earnings		(16,027	)		(15,240	)		*		(31,267	)
Net loss attributable to common stockholders		(8,088	)		(22,011	)		*		(30,099	)
Total stockholders’ equity	$	55,859		$	(6,752	)		*	$	49,107

Restated Consolidated Statement of Equity – Three Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	71,913		$	8,488			*	$	80,401
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		8,794			9,316			2,3		18,110
Additional paid-in capital, transfer to ESOP trust		513			(513	)		13		0
Additional paid-in capital, shares issued for services		1,175			283			13		1,458
Retained earnings		(16,027	)		(15,240	)		*		(31,267	)
Net loss attributable to common stockholders		(4,540	)		3,985			*		(555	)
Total stockholders’ equity	$	55,859		$	(6,752	)		*	$	49,107

Restated Consolidated Statement of Equity – Three Months Ended December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	61,366		$	(776	)		2	$	60,590
Additional paid-in capital, issuance of common shares for intangible asset acquisition		2,454			1,243			13		3,697
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		8,064			12,342			2		20,406
Additional paid-in capital, shares issued to employees		867			(351	)		13		516
Additional paid-in capital, shares issued for services		314			614			13		928
Retained earnings		(11,487	)		(19,224	)		*		(30,711	)
Net loss attributable to common stockholders		(3,548	)		(25,996	)		*		(29,544	)
Total stockholders’ equity	$	49,869		$	(19,999	)		*	$	29,870

Schedule of Restated Consolidated Statement of Cash Flows

Restated Consolidated Statement of Cash Flows – Nine Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Consolidated net loss	$	(12,238	)	$	(19,591	)		*	$	(31,827	)
Gain/loss on change in fair value of warrant liability		-			22,123			2,3		22,123
Issuance costs accrued related to warrants		-			189			1		189
Inventory		(334	)		331			8		(3	)
Stock-based compensation		-			3,429			12,13		3,429
Depreciation and amortization		1,635			(694	)		7,9		941
Net cash used by operating activities		(11,197	)		5,788			*		(5,409	)
Purchase of property and equipment		(4,509	)		(330	)		8		(4,839	)
Purchase of intangible assets		(100	)		16			*		(84	)
Purchase of long-term investments		(247	)		105			*		(142	)
Net cash used in investing activities		(41,532	)		(209	)		*		(41,741	)
Payment of issuance cost of ordinary shares		-			(1,180	)		12		(1,180	)
Proceeds from warrants exercise		-			18,038			12		18,038
Proceeds from issuance of ordinary shares		71,087			(22,437	)		12		48,650
Net Cash used in financing activities	$	71,056		$	(5,579	)		*	$	65,477

Restated Consolidated Statement of Cash Flows – Six Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Consolidated net loss	$	(8,126	)	$	(22,011	)		*	$	(30,137	)
Gain/loss on change in fair value of warrant liability		-			21,837			2,3		21,837
Issuance costs accrued related to warrants		-			189			1		189
Allowance for credit loss		-			(94	)		*		(94	)
Inventory		(343	)		270			8		(73	)
Stock based compensation		-			3,077			12,13		3,077
Depreciation and amortization		730			(225	)		7,9		505
Accounts receivable		(321	)		94			*		(227	)
Accrued expenses		(91	)		3			*		(88	)
Net cash used by operating activities		(8,076	)		3,139			*		(4,937	)
Purchase of property and equipment		(116	)		(270	)		8		(386	)
Net cash used by investing activities		(15,130	)		(205	)		*		(15,335	)
Payment of issuance cost of ordinary shares		0			(1180	)		12		(1180	)
Proceeds from issuance of ordinary shares		19,792			(1,754	)		12		18,038
Net cash provided by financing activities		19,766			(2,934	)		*		16,832

Restated Consolidated Statement of Cash Flows – Three Months Ended December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Consolidated net loss	$	(3,548	)	$	(26,017	)		*	$	(29,565	)
Gain/loss on change in fair value of warrant liability		-			25,965			2		25,965
Inventory		(248	)		60			8		(188	)
Stock based compensation		-			1,444			12,13		1,444
Depreciation and amortization		513			(232	)		7,9		281
Net cash used by operating activities		(3,578	)		1,220			*		(2,358	)
Purchase of property and equipment		(78	)		(60	)		8		(138	)
Net cash used in investing activities		(380	)		(60	)		*		(440	)
Contributions from non-controlling interests		(21	)		21			*		-
Proceeds from issuance of ordinary shares		9,244			(1,181	)		12		8,063
Net cash used in financing activities	$	9,219		$	(1,160	)		*	$	8,059

*	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Restatement of Previously Issued Financial Statements - Schedule of Restated Audited Consolidated Statement of Cash Flows (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Sep. 30, 2023

Restated Audited Consolidated Statement of Cash Flows [Line Items]

$ (29,565)

^[1]

$ (30,137)

^[1]

$ (31,827)

^[1]

$ (49,182)

$ (1,368)

Adjustment Fair Value Of Warrants

281

505

941

1,387

34,172

(5,185)

Gain on standby equity purchase agreement

(2,402)

Issuance costs related to SEPA

189

371

319

Amortization of notes payable discount

120

(188)

(73)

(3)

(96)

(207)

227

^[1]

(422)

4,218

Non-operating losses

Change in operating lease liabilities

(108)

626

221

190

Accrued expenses and other payable

(88)

^[1]

1,280

(82)

(2,358)

^[1]

(4,937)

^[1]

(5,409)

^[1]

(8,911)

(4,941)

Purchase of PPE

(138)

(386)

(4,839)

(5,144)

(844)

Purchase of short-term investments

(84)

^[1]

(590)

(5,471)

(50,028)

(15,940)

(440)

^[1]

(15,335)

^[1]

(41,741)

^[1]

(56,183)

(22,851)

Loan settlement

3,385

Net change in cash and cash equivalents

8,059

^[1]

16,832

^[1]

65,477

^[1]

236,102

41,925

171,008

14,133

Cash, cash equivalents, and restricted cash at end of period

185,574

14,566

$ 433

Restated Audited Consolidated Statement of Cash Flows [Line Items]

(3,548)

^[1]

(8,126)

^[1]

(12,238)

^[1]

(15,754)

(8,140)

Adjustment Fair Value Of Warrants

513

730

1,635

2,319

Gain on standby equity purchase agreement

Issuance costs related to SEPA

Amortization of notes payable discount

(248)

(343)

(334)

(232)

(326)

321

^[1]

(421)

Non-operating losses

(108)

Change in operating lease liabilities

518

225

Accrued expenses and other payable

(91)

^[1]

(3,578)

^[1]

(8,076)

^[1]

(11,197)

^[1]

(9,043)

(5,060)

Purchase of PPE

(78)

(116)

(4,509)

(5,009)

(725)

Purchase of short-term investments

(100)

^[1]

(591)

(5,470)

(41,975)

(380)

^[1]

(15,130)

^[1]

(41,532)

^[1]

(47,996)

(22,731)

Loan settlement

3,383

Net change in cash and cash equivalents

9,219

^[1]

19,766

^[1]

71,056

^[1]

41,923

179,063

14,132

Cash, cash equivalents, and restricted cash at end of period

193,629

Restated Audited Consolidated Statement of Cash Flows [Line Items]

(26,017)

^[1]

(22,011)

^[1]

(19,591)

^[1]

(33,428)

6,772

Adjustment Fair Value Of Warrants

(232)

(225)

(694)

(932)

34,172

(5,185)

Gain on standby equity purchase agreement

(2,402)

Issuance costs related to SEPA

189

371

319

Amortization of notes payable discount

120

270

331

136

119

(94)

^[1]

(1)

Non-operating losses

108

Change in operating lease liabilities

(108)

108

(4)

Accrued expenses and other payable

^[1]

(120)

1,220

^[1]

3,139

^[1]

5,788

^[1]

132

119

Purchase of PPE

(60)

(270)

(330)

(135)

(119)

Purchase of short-term investments

^[1]

(1)

(8,053)

(60)

^[1]

(205)

^[1]

(209)

^[1]

(8,187)

(120)

Loan settlement

Net change in cash and cash equivalents

$ (1,160)

^[1]

$ (2,934)

^[1]

$ (5,579)

^[1]

(8,055)

$ 1

Cash, cash equivalents, and restricted cash at end of period

$ (8,055)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Income Taxes (Tables)

12 Months Ended

Sep. 30, 2025

Income Taxes [Abstract]

Schedule of Difference Between the (Expense)/Benefit for Income Taxes and Income Taxes

A reconciliation of the difference between the (expense)/benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands, except amounts pertaining to rate which are shown as a percentage):

	Years Ended September 30, 2025
Federal Statutory Rate		21.00	%
Effect of:
Change in Valuation Allowance		(22.94	)%
RTP & Deferred True-up		(0.01	)%
Change in Rate		0.07	%
State Tax Benefit (Net of Fed)		1.90	%
M&E		(0.03	)%
Liability instrument issuance costs		(0.08	)%
Others		0.31	%
Total provision effective rate		0.22	%

Schedule of Deferred Tax Assets and Liabilities

The components of deferred tax assets and liabilities are as follows (in thousands):

	September 30, 2025
Deferred tax assets relating to:
Net Operating loss carryforwards	$	4,044
Research & development tax credit carryforward		7
174 Expenses		1,070
Right of Use Liability		169
Other deferred tax assets		6,843
Total gross deferred tax assets		12,133
Deferred tax liabilities relating to:
Right of Use Asset		169
Fixed Asset		18
Other deferred tax liabilities		-
Total Gross deferred tax liabilities		186
Deferred assets less liabilities		11,946
Less: valuation allowance		(11,946	)
Net deferred tax asset (liability)	$	-

Schedule of Net Operating Loss Carryforward and Research Activities Credits

The Company had the following federal net operating loss carryforward and research activities credits as of September 30, 2025 (in thousands):

Year incurred	Net Operating Loss		Research Activities Credit
2023	$	219		7.33
2024		6,588		-
2025		10,938

Restatement of Previously Issued Financial Statements - Schedule of Restated Audited Consolidated Balance Sheet (Details) - USD ($)
$ in Thousands

Sep. 30, 2025

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Sep. 30, 2024

Sep. 30, 2023

Current Assets

Cash and cash equivalents

$ 185,574

$ 14,566

$ 433

Short-term investments

66,363

15,940

1,124

$ 1,226

$ 1,296

$ 1,216

1,028

255,270

88,595

^[1]

44,944

^[1]

39,278

^[1]

32,926

Non-current assets

5,794

5,380

981

960

842

Other assets, non-current

10,715

10,568

10,865

11,057

7,620

640

740

Accrued expenses and other payables

273,673

106,325

^[1]

58,630

^[1]

52,883

^[1]

42,634

Current liabilities

1,376

Warrant liabilities

19,285

7,406

7,120

20,564

6,940

108

21,662

8,145

^[1]

7,716

^[1]

21,557

^[1]

7,395

22,209

8,892

^[1]

8,548

^[1]

22,227

^[1]

7,961

634

975

786

Stockholders’ equity

300,701

129,439

80,401

60,590

35,044

(50,241)

(32,917)

^[1]

(31,267)

^[1]

(30,711)

^[1]

(1,167)

Total liabilities, mezzanine equity and stockholders’ equity

250,830

33,887

273,673

106,325

^[1]

58,630

^[1]

52,883

^[1]

42,634

Cash and cash equivalents

Current Assets

193,629

Short-term investments

58,308

1,380

1,482

1,491

1,396

1,148

255,526

88,851

^[1]

45,139

^[1]

39,458

^[1]

33,046

Non-current assets

5,579

5,164

816

802

738

Other assets, non-current

9,761

11,532

9,384

9,576

7,621

638

Accrued expenses and other payables

272,758

107,329

^[1]

57,179

^[1]

51,424

^[1]

42,651

Current liabilities

1,377

Warrant liabilities

2,378

739

^[1]

596

^[1]

993

^[1]

455

2,925

1,378

^[1]

1,320

^[1]

1,555

^[1]

913

Stockholders’ equity

293,156

126,114

71,913

61,366

49,667

(23,693)

(20,099)

^[1]

(16,027)

^[1]

(11,487)

^[1]

(7,939)

Total liabilities, mezzanine equity and stockholders’ equity

269,833

41,738

272,758

107,329

^[1]

57,179

^[1]

51,424

^[1]

42,651

Cash and cash equivalents

Current Assets

(8,055)

Short-term investments

8,055

(256)

(195)

(180)

(120)

(256)

^[1]

(195)

^[1]

(180)

^[1]

(120)

Non-current assets

215

216

165

158

104

Other assets, non-current

954

(964)

1,481

(1)

Accrued expenses and other payables

915

(1,004)

^[1]

1,451

^[1]

1,459

^[1]

(17)

Current liabilities

(1)

Warrant liabilities

19,285

7,406

7,120

20,564

6,940

108

19,284

7,406

^[1]

7,120

^[1]

20,564

^[1]

7,048

19,284

7,514

^[1]

7,228

^[1]

20,672

^[1]

7,048

634

975

786

Stockholders’ equity

7,545

3,325

8,488

(776)

(14,623)

(26,548)

(12,818)

^[1]

(15,240)

^[1]

(19,224)

^[1]

6,772

Total liabilities, mezzanine equity and stockholders’ equity

(19,003)

(7,851)

$ 915

$ (1,004)

^[1]

$ 1,451

^[1]

$ 1,459

^[1]

$ (17)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Warrants (Tables)

12 Months Ended

Sep. 30, 2025

Warrants [Abstract]

Schedule of Warrants Outstanding

The following table summarizes warrants outstanding as of September 30, 2025 and 2024:

Instrument	Classification	Exercise Price		Expiration	September 30, 2025		September 30, 2024
Representative’s Warrants	Equity	$	6.00	Nov-28		105,000		105,000
Public Offering Warrants	Liability	$	1.35	Sep-29		3,013,408		15,555,557
Placement Agent Warrants	Mezzanine equity	$	1.69	Sep-29		616,139		1,088,889
Common Inducement Warrants	Liability	$	4.00	Feb-30		2,699,797		-
Placement Agent Inducement Warrants	Mezzanine equity	$	5.00	Mar-30		188,986		-
Total warrants outstanding						6,623,330		16,749,446

Schedule of Changes in the Liability-Classified Warrants Outstanding

The following table presents the changes in shares of the liability-classified warrants outstanding.

	Public Offering Warrants			Common Inducement Warrants		Total
Warrants outstanding as of September 30, 2023		—			—		—
Issuance		15,555,557			—		15,555,557
Warrants outstanding as of September 30, 2024		15,555,557			—		15,555,557
Issuance		—			2,699,797		2,699,797
Exercises		(12,542,149	)		—		(12,542,149	)
Warrants outstanding as of September 30, 2025		3,013,408			2,699,797		5,713,205

The following table presents the changes shares of the Mezzanine Equity Warrants.

	Placement Agent Warrants			Placement Agent Inducement Warrants		Total
Warrants outstanding as of September 30, 2023	—			—		—
Issuance		1,088,889			—		1,088,889
Warrants outstanding as of September 30, 2024		1,088,889			—		1,088,889
Issuance		—			188,986		188,986
Exercises		(472,750	)		—		(472,750	)
Warrants outstanding as of September 30, 2025		616,139			188,986		805,125

Schedule of Changes in the Fair Value of the Liability-Classified Warrants

The following table presents the change in the liability balance associated with the liability-classified warrants. Changes in the fair value of the liability-classified warrants are included within other income (loss) on the consolidated statements of operations.

	Public Offering Warrants			Common Inducement Warrants		Total
Balance as of September 30, 2023	$	—		$	—	$	—
Issuance		12,125			—		12,125
Change in fair value		(5,185	)		—		(5,185	)
Balance as of September 30, 2024		6,940			—		6,940
Issuance		—			4,758		4,758
Exercises		(26,585	)		—		(26,585	)
Change in fair value		30,648			3,524		34,172
Balance as of September 30, 2025	$	11,003		$	8,282	$	19,285

Schedule of Valuation Assumptions

Key assumptions utilized in the issuance-date valuation of the Public Offering Warrants and Common Inducement Warrants are summarized in the table below:

	Public Offering Warrants			Common Inducement Warrants
Stock price	$	1.27		$	3.01
Exercise price	$	1.35		$	4.00
Expected term (in years)		5.00			5.00
Volatility		73.6	%		75.2	%
Risk-free interest rate		3.62	%		4.29	%

Key assumptions utilized in the valuation of the liability-classified warrants as of the balance sheet dates are summarized in the table below:

	September 30, 2025			September 30, 2024
Stock price	$	4.29		$	0.84
Exercise price	$	1.35 – 4.00		$	1.35
Expected term (in years)		3.93 – 4.36			4.93
Volatility		95.1 – 100.8	%		74.9	%
Risk-free interest rate		3.64 – 3.66	%		3.55	%

Key assumptions utilized in the issuance-date valuation of the Placement Agent Warrants and Placement Agent Inducement Warrants are summarized in the table below:

	Placement Agent Warrants			Placement Agent Inducement Warrants
Stock price	$	1.27		$	1.98
Exercise price	$	1.69		$	5.00
Expected term (in years)		5.00			4.95
Volatility		73.6	%		82.7	%
Risk-free interest rate		3.62	%		3.92	%

Schedule of Mezzanine Equity

The following table summarizes activity in mezzanine equity:

	Placement Agent Warrants			Placement Agent Inducement Warrants		Total
Balance as of September 30, 2023	$	—		$	—	$	—
Issuance		786			—		786
Balance as of September 30, 2024		786			—		786
Issuance		—			189		189
Exercises		(341	)		—		(341	)
Remeasurement		—			—		—
Balance as of September 30, 2025	$	445		$	189	$	634

Fair Value of Financial Instruments (Tables)

12 Months Ended

Sep. 30, 2025

Fair Value of Financial Instruments [Abstract]

Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis

Our assets and liabilities that were measured at fair value on a recurring basis were as follows:

	September 30, 2025								September 30, 2024
	Fair Value		Level I		Level II		Level III		Fair Value		Level I		Level II		Level III
U.S. government securities	$	81,308	$	81,308	$	-	$	-	$	-	$	-	$	-	$	-
Certificates of deposit		48,656		-		48,656		-		15,940		-		15,940		-
Money market funds		45,532		45,532		-		-		-		-		-		-
Warrants		19,285		-		-		19,285		6,940		-		-		6,940
Total	$	194,781	$	126,840	$	48,656	$	19,285	$	22,880	$	-	$	15,940	$	6,940

Schedule of Cash, Cash Equivalents and Investments Classified by Security Type

Our cash, cash equivalents and investments classified by security type as of September 30, 2025 and 2024 consisted of the following:

	September 30, 2025
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-Term Investments
Cash	$	76,441	$	-	$	-	$	76,441	$	76,441	$	-
U.S. government securities		80,915		393		-		81,308		62,917		18,391
Certificates of deposit and time deposits		48,656		-		-		48,656		684		47,972
Money market funds		45,532		-		-		45,532		45,532		-
Total cash, cash equivalents and short-term investments	$	251,544	$	393	$	-	$	251,937	$	185,574	$	66,363

	September 30, 2024
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-Term Investments
Cash	$	14,566	$	-	$	-	$	14,566	$	14,566	$	-
Certificates of deposit and time deposits		15,940		-		-		15,940		-		15,940
Total cash, cash equivalents and short-term investments	$	30,506	$	-	$	-	$	30,506	$	14,566	$	15,940

Restatement of Previously Issued Financial Statements

12 Months Ended

Sep. 30, 2025

Restatement of Previously Issued Financial Statements [Abstract]

Restatement of Previously Issued Financial Statements

NOTE 2: Restatement of Previously Issued Financial Statements

We have restated our previously issued audited consolidated financial statements as of and for the years ended September 30, 2025 and 2024 (collectively, the “Affected Periods”), including the related balance sheets, statements of operations, statements of changes in stockholders’ deficit, and statements of cash flows, along with the applicable notes thereto. We determined that the restatement was necessary following the identification of errors related to the accounting for warrants, derivative instruments, and depreciation, which were not recognized or measured in accordance with U.S. GAAP in the previously issued financial statements. The restatement corrects these identified errors in the previously issued financial statements for the Affected Periods. The specific nature of these errors is described below:

Placement warrants – Placement agent warrants which should have been recognized as nonemployee share-based compensation presented within mezzanine equity were not recognized. As a result, the balance sheets did not present mezzanine equity, and subsequent exercises of placement agent warrants were improperly measured within APIC.

Pre-funded and common warrants – Pre-funded and common warrants were not correctly recognized as liabilities at issuance or subsequently measured to fair value at each reporting date. The result is that no warrants were recognized at issuance, no other income (loss) was recognized on the consolidated statements of operations due to changes in the fair value, and the accounting for the exercise of pre-funded and common warrants did not appropriately measure additional paid in capital.

Common inducement warrants – Common inducement warrants were not correctly recognized as liabilities at issuance or subsequently measured to fair value at each reporting date. The result is that no warrants were recognized at issuance, no other income (loss) was recognized on the consolidated statements of operations due to changes in the fair value, and the accounting for the exercise of common inducement warrants did not appropriately measure APIC.

SEPA and notes payable – The standby equity purchase agreement (“SEPA”) was not correctly recognized at inception or subsequently throughout the life of the agreement as a derivative instrument, and the settlement of associated notes payable issued for advances on the SEPA were not correctly recognized as settlements of liabilities through the issuance of our stock.

Cost of revenue – Certain costs incurred in the sale of our products, including event-related personnel costs, were incorrectly recognized in general and administrative expenses and sales and marketing expenses.

Research and development – Certain costs incurred in our research and development activities related to employee and contractor compensation was incorrectly recognized in general and administrative expenses.

Property and equipment – Depreciation expense was incorrectly recognized due to certain fixed assets being miscategorized.

Inventory – Purchases of certain inventory were incorrectly recognized between inventory property and equipment causing misstatements in depreciation and cost of revenue.

Intangible assets – One of our intangible assets was amortized using a useful life that was not appropriate. We revised the estimated useful life to a longer period, resulting in decreased amortization expense in the Affected Periods.

10.

Deferred tax liabilities – As a result of several of the aforementioned misstatements, our income tax provision was misstated.

11.

Short-term investments – Certain short-term investments acquired were improperly classified as cash and cash equivalents.

As a result of the errors described above, our previously issued audited consolidated financial statements for the Affected Periods were materially misstated. We have corrected these errors in the accompanying financial statements as of and for the years ended September 30, 2025 and 2024. The impact of these corrections on our consolidated financial statements for each of the Affected Periods is presented below.

Restated Audited Consolidated Balance Sheet – As of September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Assets
Current Assets
Cash and cash equivalents		193,629			(8,055	)		11		185,574
Short-term investments		58,308			8,055			11		66,363
Inventory		1,380			(256	)		8		1,124
Total current assets		255,526			(256	)		*		255,270
Non-current assets
Property and equipment, net		5,579			215			7,8		5,794
Intangible assets, net		9,761			954			9		10,715
Other assets, non-current		638			2			*		640
Total assets		272,758			915			*		273,673
Liabilities
Current liabilities
Accrued expenses and other payable		1,377			(1	)		*		1,376
Warrant liability		-			19,285			2,3		19,285
Total current liabilities		2,378			19,284			*		21,662
Total liabilities		2,925			19,284			*		22,209
Mezzanine equity		-			634			1		634
Stockholders’ equity
Additional paid-in capital		293,156			7,545			1,2,3		300,701
Retained earnings		(23,693	)		(26,548	)		*		(50,241	)
Total stockholders’ equity		269,833			(19,003	)		*		250,830
Total liabilities, mezzanine equity and stockholders’ equity		272,758			915			*		273,673

Restated Audited Consolidated Balance Sheet – As of September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Assets
Current Assets
Inventory		1,148			(120	)		8		1,028
Total current assets		33,046			(120	)		*		32,926
Non-current assets
Property and equipment, net		738			104			7,8		842
Intangible assets, net		7,621			(1	)		9		7,620
Total assets		42,651			(17	)		*		42,634
Liabilities
Current liabilities
Warrant liability		-			6,940			2,3		6,940
Total current liabilities		455			7,048			*		7,395
Deferred income taxes		-			108			10		108
Total liabilities		913			7,048			*		7,961
Mezzanine equity		-			786			1		786
Stockholders’ equity
Additional paid-in capital		49,667			(14,623	)		1,2,3,4		35,044
Retained earnings		(7,939	)		6,772			*		(1,167	)
Total stockholders’ equity		41,738			(7,851	)		*		33,887
Total liabilities, mezzanine equity and stockholders’ equity		42,651			(17	)		*		42,634

Restated Audited Consolidated Statement of Operations – Fiscal Year Ended September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Cost of revenue, net		1,756			1,479			5,8		3,235
Gross profit		3,289			(1,479	)		*		1,810
Research and development		2,432			870			6		3,302
Sales and marketing		1,262			(521	)		5		741
General and administrative		17,539			(2,572	)		5,6,7,9		14,967
Total operating expenses		21,233			(2,223	)		*		19,010
Income (loss) from operations		(17,944	)		744			*		(17,200	)
Other income (loss)		-			(34,172	)		2,3		(34,172	)
Total other expense		2,094			(34,172	)		*		(32,078	)
Loss before income tax expense		(15,850	)		(33,428	)		*		(49,278	)
Income tax benefit / (expense)		(12	)		108			10		96
Consolidated net loss		(15,862	)		(33,320	)		*		(49,182	)
Net loss attributable to common stockholders		(15,754	)		(33,320	)		*		(49,074	)
Basic and diluted net loss per share of common stock	$	(0.13	)						$	(0.40	)

Restated Audited Consolidated Statement of Operations – Fiscal Year Ended September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Cost of revenue, net		1,520			17			5,8		1,537
Gross profit		2,720			(17	)		*		2,703
Research and development		2,021			614			6		2,635
General and administrative		6,457			76			5,6,7		6,533
Total operating expenses		9,793			690			*		10,483
Income (loss) from operations		(7,073	)		(707	)		*		(7,780	)
Other income (loss)		-			7,587			2,3,4		7,587
Total other expense		(749	)		7,587			*		6,838
Loss before income tax expense		(7,822	)		6,880			*		(942	)
Income tax benefit / (expense)		(318	)		(108	)		10		(426	)
Consolidated net loss		(8,140	)		6,772			*		(1,368	)
Net loss attributable to common stockholders		(8,140	)		6,772			*		(1,368	)
Basic and diluted net loss per share of common stock	$	(0.12	)						$	(0.02	)

Restated Audited Consolidated Statement of Equity – Fiscal Year Ended September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		16,265			22,168			2,3		38,433
Additional paid-in capital		293,156			7,545			*		300,701
Net loss attributable to common stockholders		(15,754	)		(33,319	)		*		(49,073	)
Retained earnings		(23,693	)		(26,548	)		*		(50,241	)
Total stockholders’ equity		269,833			(19,003	)		*		250,830

Restated Audited Consolidated Statement of Equity – Fiscal Year Ended September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Issuance of common shares for loan settlement		3,383			(2,083	)		4		1,300
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		-			2,937			2,3		2,937
Issuance of new shares for cash		30,124			(15,487	)		2,3		14,637
Additional paid-in capital		49,667			(14,623	)		*		35,044
Net loss attributable to common stockholders		(8,140	)		6,772			*		(1,368	)
Retained earnings		(7,939	)		6,772			*		(1,167	)
Total stockholders’ equity		41,738			(7,851	)		*		33,887

Restated Audited Consolidated Statement of Cash Flows – Fiscal Year Ended September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Consolidated net loss		(15,754	)		(33,428	)		*		(49,182	)
Depreciation and amortization		2,319			(932	)		7,9		1,387
Change in fair value of warrant liability		-			34,172			2,3		34,172
Issuance costs related to warrants		-			189			1		189
Inventory		(232	)		136			8		(96	)
Accounts receivable		(421	)		(1	)		*		(422	)
Non-operating losses		(108	)		108			*		-
Deferred income taxes		-			(108	)		10		(108	)
Change in operating lease liabilities		225			(4	)		*		221
Net cash provided by operating activities		(9,043	)		132			*		(8,911	)
Purchase of PPE		(5,009	)		(135	)		8		(5,144	)
Purchase of intangible assets		(591	)		1			*		(590	)
Purchase of short-term investments		(41,975	)		(8,053	)		11		(50,028	)
Net cash used in investing activities		(47,996	)		(8,187	)		*		(56,183	)
Net change in cash and cash equivalents		179,063			(8,055	)		*		171,008
Cash, cash equivalents, and restricted cash at end of period		193,629			(8,055	)		*		185,574

Restated Audited Consolidated Statement of Cash Flows – Fiscal Year Ended September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Consolidated net loss		(8,140	)		6,772			*		(1,368	)
Change in fair value of warrant liability		-			(5,185	)		2,3		(5,185	)
Gain on standby equity purchase agreement		-			(2,402	)		4		(2,402	)
Issuance costs related to warrants		-			371			3		371
Issuance costs related to SEPA		-			319			4		319
Amortization of notes payable discount		-			120			4		120
Inventory		(326	)		119			8		(207	)
Accrued expenses and other payable		38			(120	)		4		(82	)
Deferred income taxes		518			108			10		626
Depreciation and amortization		81			17			7,9		98
Net cash provided by operating activities		(5,060	)		119			*		(4,941	)
Purchase of PPE		(725	)		(119	)		8		(844	)
Purchase of intangible assets		(5,470	)		(1	)		9		(5,471	)
Net cash used in investing activities		(22,731	)		(120	)		*		(22,851	)
Loan settlement		3,383			2			4		3,385
Net cash used in financing activities		41,923			2			*		41,925
Net change in cash and cash equivalents		14,132			1			*		14,133

*	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Intangible Asset, net (Tables)

12 Months Ended

Sep. 30, 2025

Intangible Asset, Net [Abstract]

Schedule of Intangible Asset

Intangible Asset, as of September 30, 2025 and September 30, 2024 are as follows:

	Years Ended September 30,
	2025			2024
Intangible assets	$	11,978		$	7,688
Accumulated amortization		(1,263	)		(68	)
Intangible assets, net	$	10,715		$	7,620

Schedule of Estimated Amortization Expense

Estimated amortization expense related to existing finite-lived intangible assets for each of the next five years is as follows:

Fiscal Year	Estimated Amortization Expense
FY2026	$	1,194
FY2027	$	1,194
FY2028	$	1,194
FY2029	$	1,194
FY2030	$	1,194
Total	$	5,970

Restatement of Previously Issued Financial Statements - Schedule of Restated Audited Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Restated Audited Consolidated Statement of Operations [Line Items]

Cost of revenue, net

$ 746

$ 802

$ 443

$ 1,245

$ 1,991

$ 3,235

$ 1,537

431

^[1]

365

^[1]

814

^[1]

1,179

^[1]

1,610

^[1]

1,810

2,703

Research and development

3,302

2,635

Sales and marketing

741

1,315

1,409

4,757

4,014

8,771

10,180

14,967

6,533

Income (loss) from operations

2,230

^[1]

5,447

^[1]

4,743

^[1]

10,190

^[1]

12,420

^[1]

19,010

10,483

(1,800)

^[1]

(5,082)

^[1]

(3,929)

^[1]

(9,011)

^[1]

(10,810)

^[1]

(17,200)

(7,780)

(286)

4,128

(25,965)

(21,837)

(22,123)

(34,172)

7,587

118

^[1]

4,510

^[1]

(25,636)

^[1]

(21,126)

^[1]

(21,008)

^[1]

(32,078)

6,838

Income tax benefit / (expense)

(1,681)

^[1]

(572)

^[1]

(29,565)

^[1]

(30,137)

^[1]

(31,818)

^[1]

(49,278)

(942)

^[1]

(426)

(572)

^[1]

(29,565)

^[1]

(30,137)

^[1]

(31,827)

^[1]

(49,074)

(1,368)

Basic net loss per share of common stock (in Dollars per share)

$ (1,650)

^[1]

$ (555)

^[1]

$ (29,544)

^[1]

$ (30,099)

^[1]

$ (31,749)

^[1]

$ (49,073)

$ (1,368)

$ (0.01)

$ (0)

$ (0.31)

$ (0.29)

$ (0.4)

$ (0.02)

Diluted net loss per share of common stock (in Dollars per share)

$ (0.01)

$ (0)

$ (0.31)

$ (0.29)

$ (0.4)

$ (0.02)

Restated Audited Consolidated Statement of Operations [Line Items]

Cost of revenue, net

$ 301

$ 454

$ 123

$ 577

$ 878

$ 1,756

$ 1,520

876

^[1]

713

^[1]

1,134

^[1]

1,847

^[1]

2,723

^[1]

3,289

2,720

Research and development

2,432

2,021

Sales and marketing

1,262

4,562

4,962

4,303

9,265

13,827

17,539

6,457

Income (loss) from operations

5,383

^[1]

5,652

^[1]

5,032

^[1]

10,684

^[1]

16,067

^[1]

21,233

9,793

(4,507)

^[1]

(4,939)

^[1]

(3,898)

^[1]

(8,837)

^[1]

(13,344)

^[1]

(17,944)

(7,073)

404

^[1]

382

^[1]

329

^[1]

711

^[1]

1,115

^[1]

2,094

(749)

Income tax benefit / (expense)

(4,103)

^[1]

(4,557)

^[1]

(3,569)

^[1]

(8,126)

^[1]

(12,229)

^[1]

(15,850)

(7,822)

^[1]

(12)

(318)

(4,557)

^[1]

(3,569)

^[1]

(8,126)

^[1]

(12,238)

^[1]

(15,862)

(8,140)

Basic net loss per share of common stock (in Dollars per share)

$ (4,063)

^[1]

$ (4,540)

^[1]

$ (3,548)

^[1]

$ (8,088)

^[1]

$ (12,151)

^[1]

$ (15,754)

$ (8,140)

$ (0.04)

$ (0.08)

$ (0.11)

$ (0.13)

$ (0.12)

Diluted net loss per share of common stock (in Dollars per share)

$ (0.04)

$ (0.08)

$ (0.11)

$ (0.13)

$ (0.12)

Restated Audited Consolidated Statement of Operations [Line Items]

Cost of revenue, net

$ 445

$ 348

$ 320

$ 668

$ 1,113

$ 1,479

$ 17

(445)

^[1]

(348)

^[1]

(320)

^[1]

(668)

^[1]

(1,113)

^[1]

(1,479)

(17)

Research and development

870

614

Sales and marketing

(521)

(3,153)

(205)

(289)

(494)

(3,647)

(2,572)

Income (loss) from operations

(3,153)

^[1]

(205)

^[1]

(289)

^[1]

(494)

^[1]

(3,647)

^[1]

(2,223)

690

2,707

^[1]

(143)

^[1]

(31)

^[1]

(174)

^[1]

2,534

^[1]

744

(707)

(286)

4,128

(25,965)

(21,837)

(22,123)

(34,172)

7,587

(286)

^[1]

4,128

^[1]

(25,965)

^[1]

(21,837)

^[1]

(22,123)

^[1]

(34,172)

7,587

Income tax benefit / (expense)

2,422

^[1]

3,985

^[1]

(25,996)

^[1]

(22,011)

^[1]

(19,589)

^[1]

(33,428)

6,880

^[1]

108

(108)

3,985

^[1]

(25,996)

^[1]

(22,011)

^[1]

(19,589)

^[1]

(33,320)

6,772

Restated Audited Consolidated Statement of Operations [Line Items]

$ 2,413

^[1]

$ 3,985

^[1]

$ (25,996)

^[1]

$ (22,011)

^[1]

$ (19,598)

^[1]

(33,320)

$ 6,772

As Restated [Member]

(49,182)

Shedule of Restated Consolidated Statement of Equity [Line Items]

$ (49,074)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Restatement of Previously Issued Quarterly Financial Statements - Schedule of Restated Consolidated Statement of Equity (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Sep. 30, 2023

Additional paid-in capital, issuance of common shares for intangible asset acquisition

$ 3,697

$ 3,701

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

38,514

$ 38,433

$ 2,937

Additional paid-in capital, shares issued to employees

516

692

905

Additional paid-in capital, transfer from ESOP trust

212

$ 0

Additional paid-in capital, shares issued for services

140

1,458

928

2,385

2,524

(1,650)

^[1]

(555)

^[1]

(29,544)

^[1]

(30,099)

^[1]

(31,749)

^[1]

(49,073)

(1,368)

Additional Paid-in Capital [Member]

96,458

^[1]

49,107

^[1]

29,870

^[1]

49,107

^[1]

96,458

^[1]

250,830

33,887

$ 4,809

Shedule of Restated Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

18,110

20,406

38,514

Retained Earnings [Member]

129,439

^[1]

80,401

^[1]

60,590

80,401

^[1]

129,439

^[1]

300,701

35,044

4,602

Shedule of Restated Consolidated Statement of Equity [Line Items]

Previously Reported [Member]

(32,917)

^[1]

(31,267)

^[1]

(30,711)

^[1]

(31,267)

^[1]

(32,917)

^[1]

(50,241)

(1,167)

$ 201

Shedule of Restated Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of common shares for intangible asset acquisition

2,924

2,454

5,378

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

16,265

Additional paid-in capital, shares issued to employees

867

1,380

Additional paid-in capital, transfer from ESOP trust

513

Additional paid-in capital, shares issued for services

2,591

1,175

314

1,175

4,080

(4,063)

^[1]

(4,540)

^[1]

(3,548)

^[1]

(8,088)

^[1]

(12,151)

^[1]

(15,754)

(8,140)

Previously Reported [Member] | Additional Paid-in Capital [Member]

105,951

^[1]

55,859

^[1]

49,869

^[1]

55,859

^[1]

105,951

^[1]

269,833

41,738

Shedule of Restated Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

8,794

8,064

16,858

Previously Reported [Member] | Retained Earnings [Member]

126,114

^[1]

71,913

^[1]

61,366

71,913

^[1]

126,114

^[1]

293,156

49,667

Shedule of Restated Consolidated Statement of Equity [Line Items]

Revision of Prior Period, Adjustment [Member]

(20,099)

^[1]

(16,027)

^[1]

(11,487)

^[1]

(16,027)

^[1]

(20,099)

^[1]

(23,693)

(7,939)

Shedule of Restated Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of common shares for intangible asset acquisition

(2,924)

1,243

1,247

(1,677)

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

22,168

2,937

Additional paid-in capital, shares issued to employees

(351)

(175)

(475)

Additional paid-in capital, transfer from ESOP trust

212

(513)

Additional paid-in capital, shares issued for services

(2,451)

283

614

1,210

(1,556)

2,413

^[1]

3,985

^[1]

(25,996)

^[1]

(22,011)

^[1]

(19,598)

^[1]

(33,320)

6,772

Revision of Prior Period, Adjustment [Member] | Additional Paid-in Capital [Member]

(9,493)

^[1]

(6,752)

^[1]

(19,999)

^[1]

(6,752)

^[1]

(9,493)

^[1]

(19,003)

(7,851)

Shedule of Restated Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

9,316

12,342

21,656

Revision of Prior Period, Adjustment [Member] | Retained Earnings [Member]

3,325

^[1]

8,488

^[1]

(776)

8,488

^[1]

3,325

^[1]

7,545

(14,623)

Shedule of Restated Consolidated Statement of Equity [Line Items]

Restatement of Previously Issued Financial Statements [Abstract]

$ (12,818)

^[1]

$ (15,240)

^[1]

$ (19,224)

^[1]

$ (15,240)

^[1]

$ (12,818)

^[1]

$ (26,548)

$ 6,772

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Restatement of Previously Issued Financial Statements (Tables)

12 Months Ended

Sep. 30, 2025

Schedule of Restated Audited Consolidated Statement of Operations

Restated Audited Consolidated Statement of Operations – Fiscal Year Ended September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Cost of revenue, net		1,756			1,479			5,8		3,235
Gross profit		3,289			(1,479	)		*		1,810
Research and development		2,432			870			6		3,302
Sales and marketing		1,262			(521	)		5		741
General and administrative		17,539			(2,572	)		5,6,7,9		14,967
Total operating expenses		21,233			(2,223	)		*		19,010
Income (loss) from operations		(17,944	)		744			*		(17,200	)
Other income (loss)		-			(34,172	)		2,3		(34,172	)
Total other expense		2,094			(34,172	)		*		(32,078	)
Loss before income tax expense		(15,850	)		(33,428	)		*		(49,278	)
Income tax benefit / (expense)		(12	)		108			10		96
Consolidated net loss		(15,862	)		(33,320	)		*		(49,182	)
Net loss attributable to common stockholders		(15,754	)		(33,320	)		*		(49,074	)
Basic and diluted net loss per share of common stock	$	(0.13	)						$	(0.40	)

Restated Audited Consolidated Statement of Operations – Fiscal Year Ended September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Cost of revenue, net		1,520			17			5,8		1,537
Gross profit		2,720			(17	)		*		2,703
Research and development		2,021			614			6		2,635
General and administrative		6,457			76			5,6,7		6,533
Total operating expenses		9,793			690			*		10,483
Income (loss) from operations		(7,073	)		(707	)		*		(7,780	)
Other income (loss)		-			7,587			2,3,4		7,587
Total other expense		(749	)		7,587			*		6,838
Loss before income tax expense		(7,822	)		6,880			*		(942	)
Income tax benefit / (expense)		(318	)		(108	)		10		(426	)
Consolidated net loss		(8,140	)		6,772			*		(1,368	)
Net loss attributable to common stockholders		(8,140	)		6,772			*		(1,368	)
Basic and diluted net loss per share of common stock	$	(0.12	)						$	(0.02	)

Schedule of Restated Audited Consolidated Statement of Equity

Restated Audited Consolidated Statement of Equity – Fiscal Year Ended September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		16,265			22,168			2,3		38,433
Additional paid-in capital		293,156			7,545			*		300,701
Net loss attributable to common stockholders		(15,754	)		(33,319	)		*		(49,073	)
Retained earnings		(23,693	)		(26,548	)		*		(50,241	)
Total stockholders’ equity		269,833			(19,003	)		*		250,830

Restated Audited Consolidated Statement of Equity – Fiscal Year Ended September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Issuance of common shares for loan settlement		3,383			(2,083	)		4		1,300
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		-			2,937			2,3		2,937
Issuance of new shares for cash		30,124			(15,487	)		2,3		14,637
Additional paid-in capital		49,667			(14,623	)		*		35,044
Net loss attributable to common stockholders		(8,140	)		6,772			*		(1,368	)
Retained earnings		(7,939	)		6,772			*		(1,167	)
Total stockholders’ equity		41,738			(7,851	)		*		33,887

Schedule of Restated Audited Consolidated Statement of Cash Flows

Restated Audited Consolidated Statement of Cash Flows – Fiscal Year Ended September 30, 2025

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Consolidated net loss		(15,754	)		(33,428	)		*		(49,182	)
Depreciation and amortization		2,319			(932	)		7,9		1,387
Change in fair value of warrant liability		-			34,172			2,3		34,172
Issuance costs related to warrants		-			189			1		189
Inventory		(232	)		136			8		(96	)
Accounts receivable		(421	)		(1	)		*		(422	)
Non-operating losses		(108	)		108			*		-
Deferred income taxes		-			(108	)		10		(108	)
Change in operating lease liabilities		225			(4	)		*		221
Net cash provided by operating activities		(9,043	)		132			*		(8,911	)
Purchase of PPE		(5,009	)		(135	)		8		(5,144	)
Purchase of intangible assets		(591	)		1			*		(590	)
Purchase of short-term investments		(41,975	)		(8,053	)		11		(50,028	)
Net cash used in investing activities		(47,996	)		(8,187	)		*		(56,183	)
Net change in cash and cash equivalents		179,063			(8,055	)		*		171,008
Cash, cash equivalents, and restricted cash at end of period		193,629			(8,055	)		*		185,574

Restated Audited Consolidated Statement of Cash Flows – Fiscal Year Ended September 30, 2024

Line item	As Previously Reported on 10-K			Restatement Adjustment			ID		As Restated
Consolidated net loss		(8,140	)		6,772			*		(1,368	)
Change in fair value of warrant liability		-			(5,185	)		2,3		(5,185	)
Gain on standby equity purchase agreement		-			(2,402	)		4		(2,402	)
Issuance costs related to warrants		-			371			3		371
Issuance costs related to SEPA		-			319			4		319
Amortization of notes payable discount		-			120			4		120
Inventory		(326	)		119			8		(207	)
Accrued expenses and other payable		38			(120	)		4		(82	)
Deferred income taxes		518			108			10		626
Depreciation and amortization		81			17			7,9		98
Net cash provided by operating activities		(5,060	)		119			*		(4,941	)
Purchase of PPE		(725	)		(119	)		8		(844	)
Purchase of intangible assets		(5,470	)		(1	)		9		(5,471	)
Net cash used in investing activities		(22,731	)		(120	)		*		(22,851	)
Loan settlement		3,383			2			4		3,385
Net cash used in financing activities		41,923			2			*		41,925
Net change in cash and cash equivalents		14,132			1			*		14,133

*	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Fair Value of Financial Instruments - Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	$ 194,781	$ 22,880
Level I [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	126,840
Level II [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	48,656	15,940
Level III [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	19,285	6,940
U.S. government securities [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	81,308
U.S. government securities [Member] \| Level I [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	81,308
U.S. government securities [Member] \| Level II [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
U.S. government securities [Member] \| Level III [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Certificates of deposit [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	48,656	15,940
Certificates of deposit [Member] \| Level I [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Certificates of deposit [Member] \| Level II [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	48,656	15,940
Certificates of deposit [Member] \| Level III [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Money market funds [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	45,532
Money market funds [Member] \| Level I [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	45,532
Money market funds [Member] \| Level II [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Money market funds [Member] \| Level III [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Warrants [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	19,285	6,940
Warrants [Member] \| Level I [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Warrants [Member] \| Level II [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total
Warrants [Member] \| Level III [Member]
Schedule of Assets and Liabilities that were Measured at Fair Value on a Recurring Basis [Line Items]
Total	$ 19,285	$ 6,940

Warrants - Schedule of Changes in the Liability-Classified Warrants Outstanding (Details) - shares	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Issuance	2,699,797	15,555,557
Public Offering Warrants [Member]
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Warrants outstanding, beginning	15,555,557
Issuance		15,555,557
Exercises	(12,542,149)
Warrants outstanding, ending	3,013,408	15,555,557
Common Inducement Warrants [Member]
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Warrants outstanding, beginning
Issuance	2,699,797
Exercises
Warrants outstanding, ending	2,699,797
Placement Agent Warrants [Member]
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Warrants outstanding, beginning	1,088,889
Issuance		1,088,889
Exercises	(472,750)
Warrants outstanding, ending	616,139	1,088,889
Placement Agent Inducement Warrants [Member]
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Warrants outstanding, beginning
Issuance	188,986
Exercises
Warrants outstanding, ending	188,986
Mezzanine Equity Warrants [Member]
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Warrants outstanding, beginning	1,088,889
Issuance	188,986	1,088,889
Exercises	(472,750)
Warrants outstanding, ending	805,125	1,088,889
Warrant [Member]
Schedule of Changes in the Liability-Classified Warrants Outstanding [Line Items]
Warrants outstanding, beginning	15,555,557
Exercises	(12,542,149)
Warrants outstanding, ending	5,713,205	15,555,557

Pay vs Performance Disclosure - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Pay vs Performance Disclosure

Net Income (Loss)

$ (572)

^[1]

$ (29,565)

^[1]

$ (30,137)

^[1]

$ (31,827)

^[1]

$ (49,074)

$ (1,368)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Schedule of Restated Unaudited Consolidated Balance Sheet [Line Items]

Nature of Business (Details)	12 Months Ended
Nature of Business (Details)	Sep. 30, 2025
Nature of Business [Abstract]
Incorporation date	Jun. 22, 2022

Warrants (Details) - USD ($)	Sep. 30, 2025	Sep. 30, 2024	Feb. 10, 2025	Sep. 03, 2024	Nov. 30, 2023
Placement Agent Warrants [Member]
Warrants [Line Items]
Exercise price per share	$ 1.69
Redemption value adjustment
Placement Agent Inducement Warrants [Member]
Warrants [Line Items]
Exercise price per share	$ 5
Redemption value adjustment
Liability Classified Warrants [Member]
Warrants [Line Items]
Exercise price per share			$ 4	$ 1.35
Mezzanine Equity Classified Warrants [Member]
Warrants [Line Items]
Exercise price per share		$ 1.69	$ 5
Equity Classified Warrants [Member]
Warrants [Line Items]
Exercise price per share					$ 6

Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Revenue [Line Items]
Total net revenue	$ 5,045	$ 4,240
Increase percentage revenue	19.00%
Robots-as-a-Service [Member]
Revenue [Line Items]
Total net revenue	$ 692
Robotic Sales [Member]
Revenue [Line Items]
Total net revenue	2,309
Rental Arrangements [Member]
Revenue [Line Items]
Leasing/service/rental arrangements	1,429
Retail and management services [Member]
Revenue [Line Items]
Leasing/service/rental arrangements	615
Leasing [Member]
Revenue [Line Items]
Leasing/service/rental arrangements	1,429
Service [Member]
Revenue [Line Items]
Leasing/service/rental arrangements	$ 1,429

Earnings/Loss Per Share

12 Months Ended

Sep. 30, 2025

Earnings/Loss Per Share [Abstract]

Earnings/Loss per Share

NOTE 9: Earnings/Loss per Share

Because we reported a net loss for all periods presented, no potentially dilutive securities have been included in the computation of diluted net loss per share.

The following potential common stock outstanding were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive:

		September 30, 2025				September 30, 2024
Warrants to purchase Class B common stock			6,623,330				16,749,446

	Year Ended September 30,
	2025			2024
Numerators:
Net loss attributable to common stockholders	$	(49,073	)	$	(1,368	)
Denominator:
Weighted Average ordinary shares used in computing		121,963,786			69,953,723
Basic and diluted net loss per share (in each dollar)	$	(0.40	)	$	(0.02	)

Restatement of Previously Issued Quarterly Financial Statements - Schedule of Restated Unaudited Consolidated Balance Sheet (Details) - USD ($)
$ in Thousands

Sep. 30, 2025

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Sep. 30, 2024

Sep. 30, 2023

$ 1,124

$ 1,226

$ 1,296

$ 1,216

$ 1,028

255,270

88,595

^[1]

44,944

^[1]

39,278

^[1]

32,926

5,794

5,380

981

960

842

10,715

10,568

10,865

11,057

7,620

273,673

106,325

^[1]

58,630

^[1]

52,883

^[1]

42,634

Warrant liability

19,285

7,406

7,120

20,564

6,940

Deferred Income Taxes and Other Tax Liabilities, Noncurrent

21,662

8,145

^[1]

7,716

^[1]

21,557

^[1]

7,395

108

22,209

8,892

^[1]

8,548

^[1]

22,227

^[1]

7,961

634

975

786

300,701

129,439

80,401

60,590

35,044

(50,241)

(32,917)

^[1]

(31,267)

^[1]

(30,711)

^[1]

(1,167)

Total liabilities, mezzanine equity and stockholders’ equity

250,873

96,458

^[1]

49,107

^[1]

29,870

^[1]

33,887

273,673

106,325

^[1]

58,630

^[1]

52,883

^[1]

42,634

Schedule of Restated Unaudited Consolidated Balance Sheet [Line Items]

1,380

1,482

1,491

1,396

1,148

255,526

88,851

^[1]

45,139

^[1]

39,458

^[1]

33,046

5,579

5,164

816

802

738

9,761

11,532

9,384

9,576

7,621

272,758

107,329

^[1]

57,179

^[1]

51,424

^[1]

42,651

Warrant liability

Deferred Income Taxes and Other Tax Liabilities, Noncurrent

2,378

739

^[1]

596

^[1]

993

^[1]

455

2,925

1,378

^[1]

1,320

^[1]

1,555

^[1]

913

293,156

126,114

71,913

61,366

49,667

(23,693)

(20,099)

^[1]

(16,027)

^[1]

(11,487)

^[1]

(7,939)

Total liabilities, mezzanine equity and stockholders’ equity

^[1]

105,951

55,859

49,869

272,758

107,329

^[1]

57,179

^[1]

51,424

^[1]

42,651

Schedule of Restated Unaudited Consolidated Balance Sheet [Line Items]

(256)

(195)

(180)

(120)

(256)

^[1]

(195)

^[1]

(180)

^[1]

(120)

215

216

165

158

104

954

(964)

1,481

(1)

915

(1,004)

^[1]

1,451

^[1]

1,459

^[1]

(17)

Warrant liability

19,285

7,406

7,120

20,564

6,940

Deferred Income Taxes and Other Tax Liabilities, Noncurrent

19,284

7,406

^[1]

7,120

^[1]

20,564

^[1]

7,048

108

19,284

7,514

^[1]

7,228

^[1]

20,672

^[1]

7,048

634

975

786

7,545

3,325

8,488

(776)

(14,623)

(26,548)

(12,818)

^[1]

(15,240)

^[1]

(19,224)

^[1]

6,772

Total liabilities, mezzanine equity and stockholders’ equity

^[1]

(9,493)

(6,752)

(19,999)

$ 915

$ (1,004)

^[1]

$ 1,451

^[1]

$ 1,459

^[1]

$ (17)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Income Taxes - Schedule of Income Tax Rate (Details)	12 Months Ended
Income Taxes - Schedule of Income Tax Rate (Details)	Sep. 30, 2025
Schedule of Income Tax Rate [Abstract]
Federal Statutory Rate	21.00%
Effect of:
Change in Valuation Allowance	(22.94%)
RTP & Deferred True-up	(0.01%)
Change in Rate	0.07%
State Tax Benefit (Net of Fed)	1.90%
M&E	(0.03%)
Liability instrument issuance costs	(0.08%)
Others	0.31%
Total provision effective rate	0.22%

Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Accounts Receivable, Net [Abstract]
Accounts receivable, net	$ 1,780	$ 1,359
Gross receivables	1,919
Allowance for doubtful accounts	$ 139	$ 197

Earnings/Loss Per Share - Schedule of Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Numerators:

Weighted Average ordinary shares used in computing

$ (1,650)

^[1]

$ (555)

^[1]

$ (29,544)

^[1]

$ (30,099)

^[1]

$ (31,749)

^[1]

$ (49,073)

$ (1,368)

Denominator:

121,963,786

69,953,723

Basic net loss per share (in each dollar)

$ (0.01)

$ (0)

$ (0.31)

$ (0.29)

$ (0.4)

$ (0.02)

Diluted net loss per share (in each dollar)

$ (0.01)

$ (0)

$ (0.31)

$ (0.29)

$ (0.4)

$ (0.02)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

Fair Value of Financial Instruments [Abstract]

Intangible Asset, net - Schedule of Intangible Asset (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024
Schedule of Intangible Asset [Abstract]
Intangible assets	$ 11,978				$ 7,688
Accumulated Amortization	(1,263)				(68)
Intangible assets, net	$ 10,715	$ 10,568	$ 10,865	$ 11,057	$ 7,620

Inventories

12 Months Ended

Sep. 30, 2025

Inventories [Abstract]

Inventories

NOTE 8: Inventories

Inventory as of September 30, 2025 and 2024 are as follows:

	Year Ended September 30,
	2025		2024
Raw materials	$	811	$	619
Finished goods		313		409
Total inventories	$	1,124	$	1,028

Finished goods inventory includes products-in-transit to fulfill customer orders and robotic products available for sale. We write-down inventory for any excess or obsolete inventory or when we believe that the net realizable value of inventory is less than the carrying value. During the years ended September 30, 2025, we recorded write-downs of $167, respectively, in Cost of revenues in the consolidated statements of operations.

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Sep. 30, 2025	Jan. 20, 2026
Document Information [Line Items]
Document Financial Statement Restatement Recovery Analysis [Flag]	false
Document Type	10-K/A
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	true
Entity Interactive Data Current	Yes
Amendment Flag	true
Document Period End Date	Sep. 30, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
ICFR Auditor Attestation Flag	false
Entity Registrant Name	RICHTECH ROBOTICS INC.
Entity Central Index Key	0001963685
Entity Tax Identification Number	88-2870106
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float	$ 0
Entity File Number	001-41866
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2975 Lincoln Rd
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89115
City Area Code	(866)
Local Phone Number	236-3835
Trading Symbol	RR
Title of 12(b) Security	Class B Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Amendment Description	Restatement BackgroundIn connection with the preparation and review of the Richtech Robotics Inc. (the “Company”) financial statements for the quarter ended March 31, 2026, management identified errors in the Company’s previously issued financial statements for the fiscal years ended September 30, 2025 and 2024 and unaudited interim financial statements for the periods ended December 31, 2024, March 31, 2025, June 30, 2025 and December 31, 2025 (collectively, the “Affected Financial Statements”). As a result of these findings, on June 9, 2026, the audit committee, in consultation with the Company’s management, determined that the Affected Financial Statements should no longer be relied upon.Additionally, the Company determined that any previously issued or filed reports, including financial statements, and other communications describing the Affected Financial Statements and related financial information should no longer be relied upon.The identified errors primarily relate to the Company’s accounting for warrants issued in connection with equity financing transactions, employee and nonemployee stock-based compensation arrangements, transactions executed under a Standby Equity Purchase Agreement dated as of February 15, 2024, with YA II PN, Ltd. (“SEPA”) and related notes payable, inventory and property and equipment classifications, and the classification of certain operating expenses. Specifically, the Company did not appropriately evaluate and record certain warrants, including placement agent warrants that should have been recognized as nonemployee share-based compensation and classified within mezzanine equity, as well as pre-funded warrants, common warrants, and common inducement warrants that should have been recognized as liabilities and subsequently remeasured at fair value each reporting period. As a result, certain balances were improperly classified among liabilities, mezzanine equity, and additional paid-in capital, and changes in fair value were not appropriately recognized in earnings. In addition, certain stock-based compensation awards, including awards requiring mezzanine equity classification, were improperly accounted for, resulting in misstatements of additional paid-in capital and compensation expense. The Company also identified errors in its accounting for the SEPA and related notes payable, including the failure to appropriately recognize the SEPA as a derivative instrument and to properly account for settlements of liabilities through the issuance of common stock. Further, certain costs of revenue and research and development expenses were incorrectly classified within general and administrative expenses. The Company also identified errors related to inventory and property and equipment, including the incorrect classification of certain inventory purchases as property and equipment and the miscategorization of certain fixed assets, which resulted in misstatements of inventory, property and equipment, depreciation expense, and cost of revenue. Additionally, certain intangible assets were not appropriately accounted for due to revisions to their estimated useful lives, resulting in shorter amortization periods (collectively, the “Errors”).Restatement of Previously Issued Financial StatementsThis Amendment to the Annual Report on Form 10-K/A (“Form 10-K/A”) is being filed to include audited consolidated financial statements as of and for the fiscal years ended September 30, 2025 and 2024. The Company has restated certain information within this Form 10-K/A, including the consolidated financial statements for the fiscal years ended September 30, 2025 and 2024 and certain related disclosures, as well as applicable comparative interim financial information for the quarterly periods ended December 31, 2024, March 31, 2025 and June 30, 2025 within fiscal year 2025.In addition to the restatement adjustments described above, the Company also evaluated other identified errors that were determined to be immaterial, individually and in the aggregate, to the previously issued financial statements for the impacted periods. Such items have been corrected in the period presented in this Form 10-K/A. The Company evaluated the identified misstatements in accordance with Accounting Standards Codification (“ASC”) 250, Accounting Changes and Error Corrections, and SEC Staff Accounting Bulletin No. 99 (“SAB 99”), considering both quantitative and qualitative factors. Based on this evaluation, the Company concluded that the errors were material to the previously issued financial statements for the impacted periods. Accordingly, the Company has restated the affected financial statements to reflect correction of these errors.See Note 2 and Note 3, Restatement of Previously Issued Financial Statements, to the consolidated financial statements included in Part II, Item 8 of this Form 10-K/A for additional information regarding the restatement, including a description of the Errors and the impact on the Company’s consolidated financial statements and related disclosures.Except as described above, no other information included in the original Form 10-K is being amended or updated by this Form 10-K/A and, other than as described herein, this Form 10-K/A does not purport to reflect any information or events subsequent to the original Form 10-K, including the deregistration of our joint venture company, Boyu Artificial Intelligence (Beijing) Co., Ltd. (“Boyu”), on April 3, 2026. This Form 10-K/A continues to describe the conditions as of the date of the original Form 10-K and, except as expressly contained herein, we have not updated, modified or supplemented the disclosures contained in the original Form 10-K. For updates on Boyu and other subsequent events, please see our periodic reports and current reports filed with the Securities and Exchange Commission (the “SEC”) on or after the date hereof.
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		39,934,846
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		175,161,127

Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 6,057				$ 913
Accumulated depreciation	(263)				(71)
Property and equipment, net	5,794	$ 5,380	$ 981	$ 960	842
Furniture, fixtures & equipment [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	1,435				789
Equipment held for lease [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	536				120
Leasehold improvements [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	4				4
Building [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	2,973
Land [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 1,109

Fair Value of Financial Instruments

12 Months Ended

Sep. 30, 2025

Fair Value of Financial Instruments

Note 11: Fair Value of Financial Instruments

ASC 820, Fair Value Measurements (“ASC 820”) states that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The three-tiered fair value hierarchy, which prioritizes which inputs should be used in measuring fair value, is comprised of: (Level I) observable inputs such as quoted prices in active markets; (Level II) inputs other than quoted prices in active markets that are observable either directly or indirectly and (Level III) unobservable inputs for which there is little or no market data. The fair value hierarchy requires the use of observable market data when available in determining fair value. Our assets and liabilities that were measured at fair value on a recurring basis were as follows:

	September 30, 2025								September 30, 2024
	Fair Value		Level I		Level II		Level III		Fair Value		Level I		Level II		Level III
U.S. government securities	$	81,308	$	81,308	$	-	$	-	$	-	$	-	$	-	$	-
Certificates of deposit		48,656		-		48,656		-		15,940		-		15,940		-
Money market funds		45,532		45,532		-		-		-		-		-		-
Warrants		19,285		-		-		19,285		6,940		-		-		6,940
Total	$	194,781	$	126,840	$	48,656	$	19,285	$	22,880	$	-	$	15,940	$	6,940

Our U.S. government securities are classified within Level I of the fair value hierarchy because their fair values are based on quoted prices in active markets. Our certificates of deposit are classified within Level II of the fair value hierarchy and are measured using observable market inputs.

Our liability-classified warrants are measured at fair value on a recurring basis using Level III inputs. Refer to Note 12 for details on the valuation technique and significant unobservable inputs used and a rollforward of the fair value balance.

Our cash, cash equivalents and investments classified by security type as of September 30, 2025 and 2024 consisted of the following:

	September 30, 2025
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-Term Investments
Cash	$	76,441	$	-	$	-	$	76,441	$	76,441	$	-
U.S. government securities		80,915		393		-		81,308		62,917		18,391
Certificates of deposit and time deposits		48,656		-		-		48,656		684		47,972
Money market funds		45,532		-		-		45,532		45,532		-
Total cash, cash equivalents and short-term investments	$	251,544	$	393	$	-	$	251,937	$	185,574	$	66,363

	September 30, 2024
	Adjusted Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-Term Investments
Cash	$	14,566	$	-	$	-	$	14,566	$	14,566	$	-
Certificates of deposit and time deposits		15,940		-		-		15,940		-		15,940
Total cash, cash equivalents and short-term investments	$	30,506	$	-	$	-	$	30,506	$	14,566	$	15,940

As of September 30, 2025, all of our short-term investments had contractual maturity dates within one year.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Intangible Asset, net (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Asset, net (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Intangible Asset, Net [Abstract]
Intangible asset useful lives	10 years
Amortization expenses	$ 2,150	$ 67

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Subsequent Events

12 Months Ended

Sep. 30, 2025

Subsequent Events [Abstract]

Subsequent Events

Note 15: Subsequent Events

Between October 1, 2025 and January 15, 2026, the Company issued an aggregate of 19,642,631 shares of Class B common stock, as detailed below:

The Company issued an aggregate of 4,485,946 shares of Class B common stock upon the exercise of Common Warrants, generating total proceeds of $9,813,400.08 before deducting financial advisory fees.

The Company issued an aggregate of 15,156,685 shares of Class B common stock under the At-The-Market program generating gross proceeds of $71,622,886.31.

On December 5, 2025, the Company announced the resignation of Matthew Casella as President, effective December 2, 2025. In connection with his departure, the Company entered into a separation agreement pursuant to which the Company will provide: (i) a cash payment of $32 for severance and accrued obligations, (ii) a $35 performance bonus, and (iii) 60,000 restricted shares of Class B common stock. Additionally, Mr. Casella will continue to provide consulting services for 12 months in exchange for 50,000 restricted shares of Class B common stock, payable quarterly through December 2026.

(2)

Financial Statement Schedules

All financial statement schedules are omitted because they are not applicable or the amounts are immaterial and not required, or the required information is presented in the financial statements and notes thereto beginning on page F-1 of this Report.

(3)

Exhibits

We hereby file as part of this Report the exhibits listed in the attached Exhibit Index. Exhibits that are incorporated herein by reference can be inspected on the SEC website at www.sec.gov.

Restatement of Previously Issued Financial Statements - Schedule of Restated Audited Consolidated Statement of Equity (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2025

^[1]

Mar. 31, 2025

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Sep. 30, 2023

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

$ 38,514

$ 38,433

$ 2,937

1,300

14,637

(49,073)

$ (1,650)

$ (555)

^[1]

$ (29,544)

^[1]

(30,099)

^[1]

$ (31,749)

^[1]

(49,073)

(1,368)

96,458

49,107

^[1]

29,870

^[1]

49,107

^[1]

96,458

^[1]

250,830

33,887

$ 4,809

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

16,265

3,383

30,124

(15,754)

(4,063)

(4,540)

^[1]

(3,548)

^[1]

(8,088)

^[1]

(12,151)

^[1]

(15,754)

(8,140)

105,951

55,859

^[1]

49,869

^[1]

55,859

^[1]

105,951

^[1]

269,833

41,738

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

22,168

2,937

(2,083)

(15,487)

(33,319)

2,413

3,985

^[1]

(25,996)

^[1]

(22,011)

^[1]

(19,598)

^[1]

(33,320)

6,772

Additional Paid-in Capital [Member]

(9,493)

(6,752)

^[1]

(19,999)

^[1]

(6,752)

^[1]

(9,493)

^[1]

(19,003)

(7,851)

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

18,110

20,406

38,514

1,300

Additional Paid-in Capital [Member] | As Previously Reported [Member]

129,439

80,401

^[1]

60,590

80,401

^[1]

129,439

^[1]

300,701

35,044

4,602

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

8,794

8,064

16,858

Additional Paid-in Capital [Member] | Restatement Adjustment [Member]

126,114

71,913

^[1]

61,366

71,913

^[1]

126,114

^[1]

293,156

49,667

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Additional paid-in capital, issuance of shares upon exercise of warrants for cash

9,316

12,342

21,656

Retained Earnings [Member]

3,325

8,488

^[1]

(776)

8,488

^[1]

3,325

^[1]

7,545

(14,623)

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Retained Earnings [Member] | As Previously Reported [Member]

(32,917)

(31,267)

^[1]

(30,711)

^[1]

(31,267)

^[1]

(32,917)

^[1]

(50,241)

(1,167)

$ 201

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Retained Earnings [Member] | Restatement Adjustment [Member]

(20,099)

(16,027)

^[1]

(11,487)

^[1]

(16,027)

^[1]

(20,099)

^[1]

(23,693)

(7,939)

Schedule of Restated Audited Consolidated Statement of Equity [Line Items]

Schedule of Restated Consolidated Statement of Operations [Line Items]

$ (12,818)

$ (15,240)

^[1]

$ (19,224)

^[1]

$ (15,240)

^[1]

$ (12,818)

^[1]

$ (26,548)

$ 6,772

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Restatement of Previously Issued Quarterly Financial Statements - Schedule of Restated Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Mar. 31, 2025

Jun. 30, 2025

Sep. 30, 2025

Sep. 30, 2024

Cost of revenues

$ 746

$ 802

$ 443

$ 1,245

$ 1,991

$ 3,235

$ 1,537

431

^[1]

365

^[1]

814

^[1]

1,179

^[1]

1,610

^[1]

1,810

2,703

1,409

4,757

4,014

8,771

10,180

14,967

6,533

2,230

^[1]

5,447

^[1]

4,743

^[1]

10,190

^[1]

12,420

^[1]

19,010

10,483

Loss from operations

(1,800)

^[1]

(5,082)

^[1]

(3,929)

^[1]

(9,011)

^[1]

(10,810)

^[1]

(17,200)

(7,780)

(286)

4,128

(25,965)

(21,837)

(22,123)

(34,172)

7,587

118

^[1]

4,510

^[1]

(25,636)

^[1]

(21,126)

^[1]

(21,008)

^[1]

(32,078)

6,838

Income tax benefit/(expense)

(1,681)

^[1]

(572)

^[1]

(29,565)

^[1]

(30,137)

^[1]

(31,818)

^[1]

(49,278)

(942)

(9)

^[1]

(96)

426

^[1]

(1,690)

(572)

^[1]

(29,565)

^[1]

(30,137)

^[1]

(31,827)

^[1]

(49,074)

(1,368)

Basic net loss per share of common stock (in Dollars per share)

$ (1,650)

^[1]

$ (555)

^[1]

$ (29,544)

^[1]

$ (30,099)

^[1]

$ (31,749)

^[1]

$ (49,073)

$ (1,368)

$ (0.01)

$ (0)

$ (0.31)

$ (0.29)

$ (0.4)

$ (0.02)

Diluted net loss per share of common stock (in Dollars per share)

$ (0.01)

$ (0)

$ (0.31)

$ (0.29)

$ (0.4)

$ (0.02)

Schedule of Restated Consolidated Statement of Operations [Line Items]

Cost of revenues

$ 301

$ 454

$ 123

$ 577

$ 878

$ 1,756

$ 1,520

876

^[1]

713

^[1]

1,134

^[1]

1,847

^[1]

2,723

^[1]

3,289

2,720

4,562

4,962

4,303

9,265

13,827

17,539

6,457

5,383

^[1]

5,652

^[1]

5,032

^[1]

10,684

^[1]

16,067

^[1]

21,233

9,793

Loss from operations

(4,507)

^[1]

(4,939)

^[1]

(3,898)

^[1]

(8,837)

^[1]

(13,344)

^[1]

(17,944)

(7,073)

404

^[1]

382

^[1]

329

^[1]

711

^[1]

1,115

^[1]

2,094

(749)

Income tax benefit/(expense)

(4,103)

^[1]

(4,557)

^[1]

(3,569)

^[1]

(8,126)

^[1]

(12,229)

^[1]

(15,850)

(7,822)

^[1]

318

^[1]

(4,103)

(4,557)

^[1]

(3,569)

^[1]

(8,126)

^[1]

(12,238)

^[1]

(15,862)

(8,140)

Basic net loss per share of common stock (in Dollars per share)

$ (4,063)

^[1]

$ (4,540)

^[1]

$ (3,548)

^[1]

$ (8,088)

^[1]

$ (12,151)

^[1]

$ (15,754)

$ (8,140)

$ (0.04)

$ (0.08)

$ (0.11)

$ (0.13)

$ (0.12)

Diluted net loss per share of common stock (in Dollars per share)

$ (0.04)

$ (0.08)

$ (0.11)

$ (0.13)

$ (0.12)

Schedule of Restated Consolidated Statement of Operations [Line Items]

Cost of revenues

$ 445

$ 348

$ 320

$ 668

$ 1,113

$ 1,479

$ 17

(445)

^[1]

(348)

^[1]

(320)

^[1]

(668)

^[1]

(1,113)

^[1]

(1,479)

(17)

(3,153)

(205)

(289)

(494)

(3,647)

(2,572)

(3,153)

^[1]

(205)

^[1]

(289)

^[1]

(494)

^[1]

(3,647)

^[1]

(2,223)

690

Loss from operations

2,707

^[1]

(143)

^[1]

(31)

^[1]

(174)

^[1]

2,534

^[1]

744

(707)

(286)

4,128

(25,965)

(21,837)

(22,123)

(34,172)

7,587

(286)

^[1]

4,128

^[1]

(25,965)

^[1]

(21,837)

^[1]

(22,123)

^[1]

(34,172)

7,587

Income tax benefit/(expense)

2,422

^[1]

3,985

^[1]

(25,996)

^[1]

(22,011)

^[1]

(19,589)

^[1]

(33,428)

6,880

(9)

^[1]

(108)

108

^[1]

2,413

3,985

^[1]

(25,996)

^[1]

(22,011)

^[1]

(19,589)

^[1]

(33,320)

6,772

Summary of Significant Accounting Policies [Abstract]

$ 2,413

^[1]

$ 3,985

^[1]

$ (25,996)

^[1]

$ (22,011)

^[1]

$ (19,598)

^[1]

$ (33,320)

$ 6,772

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Warrants

12 Months Ended

Sep. 30, 2025

Warrants [Abstract]

Warrants

Note 12: Warrants

The following table summarizes warrants outstanding as of September 30, 2025 and 2024:

Instrument	Classification	Exercise Price		Expiration	September 30, 2025		September 30, 2024
Representative’s Warrants	Equity	$	6.00	Nov-28		105,000		105,000
Public Offering Warrants	Liability	$	1.35	Sep-29		3,013,408		15,555,557
Placement Agent Warrants	Mezzanine equity	$	1.69	Sep-29		616,139		1,088,889
Common Inducement Warrants	Liability	$	4.00	Feb-30		2,699,797		-
Placement Agent Inducement Warrants	Mezzanine equity	$	5.00	Mar-30		188,986		-
Total warrants outstanding						6,623,330		16,749,446

Liability Classified Warrants

On September 3, 2024, in connection with a registered public offering, we issued warrants to investors (the “Public Offering Warrants”) with an exercise price of $1.35 per share. In connection with the inducement transaction on February 10, 2025, we issued new common stock purchase warrants to certain holders that exercised outstanding warrants (the “Common Inducement Warrants”) with an exercise price of $4.00 per share. The Public Offering Warrants were issued to investors in exchange for capital, and the Common Inducement Warrants were issued in exchange for the exercise of previously outstanding warrants. The terms of the Public Offering Warrants and Common Inducement Warrants include settlement features that, under specified transactions involving a change in control or similar corporate events, could require the Company to settle the warrants for cash in circumstances outside the Company’s control. As a result, the warrants do not qualify for equity classification and are recorded as liabilities, measured initially and subsequently at fair value with changes in fair value recognized in earnings.

The following table presents the changes in shares of the liability-classified warrants outstanding.

	Public Offering Warrants			Common Inducement Warrants		Total
Warrants outstanding as of September 30, 2023		—			—		—
Issuance		15,555,557			—		15,555,557
Warrants outstanding as of September 30, 2024		15,555,557			—		15,555,557
Issuance		—			2,699,797		2,699,797
Exercises		(12,542,149	)		—		(12,542,149	)
Warrants outstanding as of September 30, 2025		3,013,408			2,699,797		5,713,205

Both the Public Offering Warrants and the Common Inducement Warrants are included within Level III of the fair value hierarchy. We use a Black-Scholes option pricing model to determine the fair value of our liability-classified warrants. The valuation incorporates both observable inputs, including our stock price and risk-free interest rates, and significant unobservable inputs, including expected stock price volatility. The expected volatility is based on a combination of the implied volatility of our publicly traded common stock and the historical volatility of comparable publicly traded companies with similar expected terms, while the expected term is generally based on the contractual term of the warrants as they are immediately exercisable. The dividend yield is assumed to be zero, consistent with our historical practice on our Class B common stock. Changes in significant unobservable inputs, particularly expected volatility and expected term, could result in a significantly higher or lower fair value measurement.

Key assumptions utilized in the issuance-date valuation of the Public Offering Warrants and Common Inducement Warrants are summarized in the table below:

	Public Offering Warrants			Common Inducement Warrants
Stock price	$	1.27		$	3.01
Exercise price	$	1.35		$	4.00
Expected term (in years)		5.00			5.00
Volatility		73.6	%		75.2	%
Risk-free interest rate		3.62	%		4.29	%

	Public Offering Warrants			Common Inducement Warrants		Total
Balance as of September 30, 2023	$	—		$	—	$	—
Issuance		12,125			—		12,125
Change in fair value		(5,185	)		—		(5,185	)
Balance as of September 30, 2024		6,940			—		6,940
Issuance		—			4,758		4,758
Exercises		(26,585	)		—		(26,585	)
Change in fair value		30,648			3,524		34,172
Balance as of September 30, 2025	$	11,003		$	8,282	$	19,285

Key assumptions utilized in the valuation of the liability-classified warrants as of the balance sheet dates are summarized in the table below:

	September 30, 2025			September 30, 2024
Stock price	$	4.29		$	0.84
Exercise price	$	1.35 – 4.00		$	1.35
Expected term (in years)		3.93 – 4.36			4.93
Volatility		95.1 – 100.8	%		74.9	%
Risk-free interest rate		3.64 – 3.66	%		3.55	%

Mezzanine Equity Classified Warrants

In September 2024, in connection with a registered public offering, we issued warrants to placement agents (the “Placement Agent Warrants”) with an exercise price of $1.69 per share. In connection with the inducement transaction on February 10, 2025, we issued inducement warrants to certain placement agents with an exercise price of $5.00 (the “Placement Agent Inducement Warrants,” and together with the Placement Agent Warrants, the “Mezzanine Equity Warrants”). The Placement Agent Warrants were issued on September 3, 2024, and the Placement Agent Inducement Warrants were issued on March 12, 2025. Both were issued in exchange for placement agent services and are accounted for as share-based payment awards. Due to certain settlement features that are not solely within the Company’s control, including a change in control or similar corporate events, the Mezzanine Equity Warrants are classified within mezzanine equity. The warrants were recorded at their issuance-date fair value. As of September 30, 2025 and 2024, the warrants were not currently redeemable and, therefore, the Company did not adjust the carrying amounts to redemption value. The warrants are exercisable into shares of Class B common stock.

The following table presents the changes shares of the Mezzanine Equity Warrants.

	Placement Agent Warrants			Placement Agent Inducement Warrants		Total
Warrants outstanding as of September 30, 2023	—			—		—
Issuance		1,088,889			—		1,088,889
Warrants outstanding as of September 30, 2024		1,088,889			—		1,088,889
Issuance		—			188,986		188,986
Exercises		(472,750	)		—		(472,750	)
Warrants outstanding as of September 30, 2025		616,139			188,986		805,125

Key assumptions utilized in the issuance-date valuation of the Placement Agent Warrants and Placement Agent Inducement Warrants are summarized in the table below:

	Placement Agent Warrants			Placement Agent Inducement Warrants
Stock price	$	1.27		$	1.98
Exercise price	$	1.69		$	5.00
Expected term (in years)		5.00			4.95
Volatility		73.6	%		82.7	%
Risk-free interest rate		3.62	%		3.92	%

The following table summarizes activity in mezzanine equity:

	Placement Agent Warrants			Placement Agent Inducement Warrants		Total
Balance as of September 30, 2023	$	—		$	—	$	—
Issuance		786			—		786
Balance as of September 30, 2024		786			—		786
Issuance		—			189		189
Exercises		(341	)		—		(341	)
Remeasurement		—			—		—
Balance as of September 30, 2025	$	445		$	189	$	634

Because the Placement Agent Warrants and Placement Agent Inducement Warrants were not currently redeemable as of September 30, 2025 or September 30, 2024, no redemption value adjustment was recorded during the years ended September 30, 2025 and 2024.

Equity Classified Warrants

In connection with our initial public offering in November 2023, we issued warrants with an exercise price of $6.00 per share to the representative of the offering to purchase shares of our common stock (the “Representative’s Warrants”). The Representative’s Warrants were issued as consideration for underwriting services and are accounted for as share-based payment awards. The Representative’s Warrants do not contain any cash settlement or redemption features outside the Company’s control, and are classified in permanent equity. The Representative’s Warrants issued at our initial public offering remained outstanding as of both September 30, 2025 and September 30, 2024, with no issuances, exercises, forfeitures, or expirations during the period from September 30, 2024 through September 30, 2025.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Sep. 30, 2025

Schedule of Property and Equipment

Property and equipment, as of September 30, 2025 and 2024 are as follows:

	Years Ended September 30,
	2025			2024
Furniture, fixtures & equipment	$	1,435		$	789
Equipment held for lease		536			120
Leasehold improvements		4			4
Building		2,973			-
Land		1,109			-
		6,057			913
Accumulated depreciation		(263	)		(71	)
Property and equipment, net	$	5,794		$	842

Summary of Significant Accounting Policies

12 Months Ended

Sep. 30, 2025

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 4: Summary of Significant Accounting Policies

Basis of Presentation

These financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. We view our operations and manage our business as one operating segment.

Cash and Cash Equivalents

We consider all highly liquid investments purchased with original maturity of three months or less to be cash equivalents. We place our cash and cash equivalents in highly liquid instruments with, and in the custody of, financial institutions with high credit ratings.

Investments

Investments may be comprised of a combination of marketable securities, including U.S. government securities, corporate debt securities, commercial paper, time deposits, and certain certificates of deposit, which are all designated as available-for-sale and reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive income which is included within stockholders’ equity.

Available-for-sale marketable securities with maturities greater than three months at the date of purchase are included in short-term investments in our consolidated balance sheets. Interest, dividends, amortization and accretion of purchase premiums and discounts on these investments are included within Interest income in our consolidated statements of operations.

The cost of available-for-sale investments sold is based on the specific identification method. Realized gains and losses on the sale of available-for-sale investments are recorded in Other income (expense), net.

We regularly review all of our investments for declines in fair value. The review includes but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers. The amortized cost basis of our investments approximates its fair value.

Warrants

We have issued certain warrants that are classified as either liabilities or equity. Warrants classified as liabilities are measured at fair value at each reporting period end. Prefunded warrants for which the only valuation input is the quoted price of our common stock are valued using observable market prices and, when outstanding, are classified within Level 1 of the fair value hierarchy. All other liability-classified warrants are valued using an option pricing model, such as the Black-Scholes model, which incorporates inputs including the expected volatility of our common stock, the expected term of the warrant, a risk-free interest rate based on U.S. Treasury yields, and an expected dividend yield of zero. Because these valuations include significant unobservable inputs, such warrants are classified within Level 3 of the fair value hierarchy. Changes in the fair value of liability-classified warrants are recognized in earnings in the period of change.

For equity-classified warrants, fair value is measured at issuance with no subsequent remeasurement.

Standby Equity Purchase Agreement

We entered into a standby equity purchase agreement that provides us the right, subject to certain terms and conditions, to sell shares of our Class B common stock to an investor from time to time. We evaluate the terms of the standby equity purchase agreement to determine the appropriate accounting treatment under applicable accounting guidance. Certain provisions of the arrangement permitted the issuance of a variable number of shares based on future market prices and other contractual terms of the arrangement. As a result, the arrangement was accounted for as a derivative liability. We recognize the derivative liability at fair value upon inception of the arrangement and subsequently remeasure the derivative liability at fair value at each reporting period end. Changes in the fair value of the derivative liability are recognized in earnings in the period of change.

Accounts Receivable

Our accounts receivable primarily consist of trade receivables, which represent amounts owed to us by customers for products and services provided. These receivables are presented net of any rebates, price protection adjustments, and an allowance for credit losses. In addition to trade receivables, our accounts receivable also include unbilled receivables. These primarily relate to work completed on development services for which revenue has been recognized but not yet invoiced to customers. We expect these unbilled receivables to be billed and collected within twelve months.

We actively manage our exposure to customer credit risk through various measures, including credit limits, credit lines, ongoing monitoring procedures, and credit approvals. We perform in-depth credit evaluations of all new customers and periodically reassess the creditworthiness of existing customers. If deemed necessary, we may require letters of credit, bank or corporate guarantees, or advance payments to mitigate credit risk.

To account for potential losses from uncollectible accounts, we maintain an allowance for credit losses. This allowance considers both specific troubled accounts and an overall estimate of potential uncollectible receivables based on historical experience and current credit quality assessments. As of September 30, 2025, the allowance for credit losses was $139, compared to $197 as of September 30, 2024. We believe that our rigorous credit risk management practices and the allowance for credit losses adequately address the potential for uncollectible accounts.

Inventories

We value inventory at standard cost, adjusted to approximate the lower of actual cost or estimated net realizable value using assumptions about future demand and market conditions. In determining excess or obsolescence reserves for our products, we consider assumptions such as changes in business and economic conditions, other-than-temporary decreases in demand for our products, and changes in technology or customer requirements. In determining the lower of cost or net realizable value reserves, we consider assumptions such as recent historical sales activity and selling prices, as well as estimates of future selling prices. We fully reserve for inventories and non-cancellable purchase orders for inventory deemed obsolete. We perform periodic reviews of inventory items to identify excess inventories on hand by comparing on-hand balances and non-cancellable purchase orders to anticipated usage using recent historical activity as well as anticipated or forecasted demand. If estimates of customer demand diminish further or market conditions become less favorable than those projected by us, additional inventory carrying value adjustments may be required.

Property, and Equipment, net

Property and equipment, net is stated at cost less accumulated depreciation and amortization and is depreciated using the straight-line method over the estimated useful lives of the assets. Estimated useful lives of equipment is two to six years, and leasehold improvements are measured by the shorter of the remaining terms of the leases or the estimated useful economic lives of the improvements.

Property and equipment, as of September 30, 2025 and 2024 are as follows:

	Years Ended September 30,
	2025			2024
Furniture, fixtures & equipment	$	1,435		$	789
Equipment held for lease		536			120
Leasehold improvements		4			4
Building		2,973			-
Land		1,109			-
		6,057			913
Accumulated depreciation		(263	)		(71	)
Property and equipment, net	$	5,794		$	842

Depreciation expenses for 2025 and 2024 were $192 and $31, respectively.

Rights and Privileges of Common Stock

Pursuant to our second amended and restated articles of incorporation, our authorized capital stock consists of an aggregate of 300,000,000 shares of common stock, including 100,000,000 shares of Class A common stock and 200,000,000 shares of Class B common stock, and 10,000,000 shares of “blank check” preferred stock. The following description summarizes the material terms of our securities registered under Section 12 of the Exchange Act and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our second amended and restated articles of incorporation and our amended and restated bylaws.

Except as otherwise required by Nevada Revised Statutes (“NRS”), each holder of Class A common stock is entitled to ten (10) votes in respect of each share of Class A common stock held by him, her, or it of record on the books of the Company, and each holder of Class B common stock is entitled to one (1) vote in respect of each share of Class B common stock held by him, her, or it of record on the books of the Company, in connection with the election of directors and on all matters submitted to a vote of stockholders of the Company. Each share of Class A common stock is convertible into one share of Class B common stock at any time at the option of the holder, but Class B common stock shall not be convertible into Class A common stock under any circumstances. Holders of our common stock do not have preemptive, subscription, or redemption rights.

Listing on Nasdaq

On November 17, 2023, the Company’s shares of Class B common stock commenced trading on the Nasdaq Capital Market under the ticker symbol “RR.”

Mezzanine Equity

We classify certain equity instruments as mezzanine equity when they contain redemption features that are not solely within our control. Under ASC 480-10-S99-3A and SEC Regulation S-X Rule 5-02, instruments that are redeemable for cash or other assets upon the occurrence of events not solely within our control are presented outside of permanent equity in a separate mezzanine section of the consolidated balance sheets.

Mezzanine equity instruments are initially measured at fair value on the issuance date. Subsequent measurement is based on the estimated redemption value, with changes in the carrying amount recognized through accretion to retained earnings (or additional paid-in capital if retained earnings is insufficient) as redemption becomes probable. We classify mezzanine equity in a separate caption between liabilities and stockholders’ equity on the balance sheet and disclose the terms of each issue, including redemption features and dividend rights.

Revenue Recognition

Revenue is recognized when we transfer promised goods or services to our customers, in amounts that reflect the consideration that we expect to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each agreement, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.

For arrangements that bundle robotic products, maintenance, and technical support services, we exercise significant judgment in determining whether these items are distinct. Robotic products are typically considered distinct performance obligations as customers can benefit from the product on its own. Maintenance and technical support services, which may include scheduled inspections, repairs, remote troubleshooting, and spare parts provisions, are generally considered distinct performance obligations when they are separately priced, optional, and can be performed by another vendor. However, when these services are embedded as a mandatory component of a bundled contract (e.g., a RaaS arrangement) and are integral to the promised continuous operational capability, they are not considered distinct and are combined with the overall service promise as a single performance obligation. We allocate the transaction price to each distinct performance obligation based on its relative standalone selling price, which is determined based on observable standalone sales or, if not available, estimated using expected cost-plus-margin approaches.

We recognize revenue when control of a promised good or service transfers to a customer. Control can transfer at a point in time or over time. Revenue from the sale of robotic products is recognized at a point in time, typically upon shipment or delivery when legal title and the significant risks and rewards of ownership have transferred to the customer. This is assessed based on the terms of sale (e.g., FOB shipping point or FOB destination) and when the customer obtains physical possession, bears the risk of loss, and has an unconditional obligation to pay. Revenue from Robotics-as-a-Service (RaaS) arrangements is recognized over time, as the customer simultaneously receives and consumes the benefits of the Company’s continuous provision of robotic functionality, maintenance, and technical support services. The Company uses the straight-line method of recognition over the contract term as the most faithful depiction of the transfer of services, unless evidence suggests another method better reflects the pattern of performance. The assessment of whether control transfers over time is based on the criteria in ASC 606, including whether (a) the customer simultaneously receives and consumes benefits as the Company performs, or (b) the Company’s performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date.

The transaction price is the amount of consideration to which we expect to be entitled in exchange for transferring promised goods or services to a customer. Our contracts contain fixed consideration. We do not offer variable consideration elements such as usage-based fees, price concessions, rebates, penalties, or performance bonuses. Therefore, the transaction price for all contracts equals the fixed, non-refundable amount stated in the contract.

At contract inception, we assess the customer’s ability and intent to pay the promised consideration. A contract is only accounted for under ASC 606 if it is probable we will collect substantially all of the consideration to which it is entitled. This collectability assessment involves evaluating the customer’s creditworthiness using both quantitative and qualitative factors. For new customers, this includes reviewing credit ratings (if available), financial statements, and payment history with other parties. For existing customers, we review historical payment patterns, current financial health, and the impact of prevailing economic conditions. If, after contract inception, a significant deterioration in a customer’s creditworthiness indicates that collectability of substantially all of the remaining consideration is no longer probable, we cease to recognize additional revenue and assesses the need for a credit loss provision on any recognized contract assets or receivables.

Product Revenue

We generate revenue through the sale of our branded robotic products directly to customers. We consider customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with our customers. There is a single performance obligation in all our contracts, which is our promise to transfer our product to customers based on specific payment and shipping terms in the arrangement. The entire transaction price is allocated to this single performance obligation. Product revenue is recognized when a customer obtains control of our product, which occurs at a point in time and may be upon shipment or delivery, based on the terms of the contract.

Revenue from Robots-as-a-Service (RaaS)

As part of our evolving business model, we generate revenue through our Robots-as-a-Service (RaaS) offerings, which provide customers with ongoing access to our robotic solutions under long-term contracts. For RaaS agreements, revenue is recognized over time on a monthly basis as the services are provided and the customer benefits from the use of the robotic solutions.

The transaction price is typically fixed and allocated evenly across the contract term. Revenue recognition begins once the robots are installed and operational at the customer’s site. We account for RaaS arrangements under ASC 606, Revenue from Contracts with Customers. These contracts provide customers with continuous usage to the Company’s robotic products, maintenance, and technical support services, in exchange for a fixed fee. The Company has determined that these are service contracts, as the customer is contracting for an integrated service output and the Company retains substantial ownership risks and control over the deployed robotic assets, including responsibility for maintenance, upgrades, and ensuring uptime. The customer does not have the right to direct the use of, nor obtain substantially all the economic benefits from, a specifically identified asset. Revenue from these fixed-fee contracts is recognized on a straight-line basis over the contractual service period as the customer simultaneously receives and consumes the benefits.

Revenue from Leasing

We account for Robotic leasing arrangements under ASC 842, Leases. These contracts convey the right to control the use of an explicitly identified robotic products for a specified period in exchange for consideration. As the customer has the right to direct the use of and obtain substantially all economic benefits from the specifically identified asset during the lease term, these contracts meet the definition of a lease. Our leases are classified as operating leases, and lease income is recognized on a straight-line basis over the lease term. The leased robot is included within Property, Plant, and Equipment and depreciated over its useful life. We did not generate revenue from lease arrangements in fiscal year 2025.

Remaining Performance Obligations

Remaining performance obligations represent the aggregate amount of the transaction price allocated to unsatisfied or partially unsatisfied performance obligations as of the balance sheet date. This amount relates primarily to the fixed consideration in non-cancelable Robotics-as-a-Service (RaaS) contracts for which revenue is recognized over time.

As of September 30, 2025, the total amount of the transaction price allocated to remaining performance obligations was $1,376. Of this amount, $704 is expected to be recognized as revenue within the next 12 months, $425 is expected to be recognized between 13 and 24 months, and the remaining $247 is expected to be recognized beyond 24 months. We did not generate revenue from leasing arrangements in fiscal year 2025, and as such, there are no remaining performance obligations related to lease contracts.

Contract assets and contract liabilities

We maintain contract-related balance sheet accounts under ASC 606, Revenue from Contracts with Customers, which primarily arise from Robotics-as-a-Service (RaaS) arrangements.

Contract Assets (Unbilled Receivables) represent revenue recognized for performance obligations satisfied but not yet billed as of the balance sheet date. These assets are generated when revenue is recognized over time under RaaS contracts, while invoicing occurs on a periodic or milestone basis. Contract assets are reclassified to accounts receivable when the right to payment becomes unconditional.

Contract Liabilities (Deferred Revenue) consist of payments received from customers in advance of performance. These liabilities relate primarily to advance payments for RaaS subscriptions and are recognized as revenue as the related services are provided over the contract term. As of September 30, 2025, the balance of contract liabilities was $248.

No contract balances are attributable to leasing activities, as the Company did not generate revenue from lease arrangements during fiscal year 2025.

Other Revenue Policies

Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised products to the customer will be one year or less, which is the case with substantially all customers.

We recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that we otherwise would have recognized is one year or less. These costs are included in selling expenses.

We account for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.

We record the related costs within cost of goods sold.

Research and Development Costs

Research and development costs primarily consist of employee-related expenses, including salaries and benefits, facilities costs, depreciation, and other allocated expenses. Research and development costs are expensed as incurred.

Income Taxes

The Company accounts for income taxes in accordance with income tax accounting guidance (Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 740, Income Taxes). The income tax accounting guidance results in two components of income tax expense: current and deferred. Current income tax expense reflects taxes to be paid or refunded for the current period by applying the provisions of the enacted tax law to the taxable income or excess of deductions over revenues. The Company determines deferred income taxes using the liability (or balance sheet) method. Under this method, the net deferred tax asset or liability is based on the tax effects of the differences between the book and tax bases of assets and liabilities, and enacted changes in tax rates and laws are recognized in the period in which they occur. Deferred income tax expense results from changes in deferred tax assets and liabilities between periods. Deferred tax assets are reduced by a valuation allowance if, based on the weight of evidence available, it is more likely than not some portion or all of a deferred tax asset will not be realized.

Tax positions are recognized if it is more likely than not, based on the technical merits, the tax position will be realized or sustained upon examination. The term “more likely than not” means a likelihood of more than 50 percent; the terms examined and upon examination also include resolution of the related appeals or litigation processes, if any. A tax position that meets the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50 percent likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances and information available at the reporting date and is subject to management’s judgment.

The Company recognizes interest and penalties on income taxes as a component of income tax expense.

Recent Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (“Topic 842”). The guidance in this ASU supersedes the leasing guidance in Topic 840, Leases. Under the new guidance, lessees are required to recognize lease assets and lease liabilities on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The standard is effective for public business entities for fiscal years beginning after December 15, 2018. As an emerging growth company, we adopted the new standard on January 1, 2022 for our years ended September 30, 2024 and 2025. We had operating leases for which we were required to recognize a right-of-use asset and lease liability.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which amends the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The new standard allows certain exceptions, including an exception to the use of the incremental approach for intra-period tax allocation, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also requires franchise or similar taxes partially based on income to be reported as income tax and to reflect the effects of enacted changes in tax laws or rates in the annual effective tax rate computation from the date of enactment. Lastly, in any future acquisition, we would be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard was effective for us beginning January 1, 2022, with early adoption of the amendments permitted. The adoption of ASU 2019-12 did not have a material impact on our financial statements and disclosures.

In May 2020, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815- 40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another topic. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021. The Company has determined the adoption of ASU 2021-04 did not have a material impact on our financial statements and disclosures.

Warrants - Schedule of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Schedule of Warrants Outstanding [Line Items]
Total warrants outstanding	6,623,330	16,749,446
Representative’s Warrants [Member]
Schedule of Warrants Outstanding [Line Items]
Instrument Exercise Price	$ 6
Instrument Expiration	Nov-28
Total warrants outstanding	105,000	105,000
Warrants Outstanding Classification	Equity
Public Offering Warrants [Member]
Schedule of Warrants Outstanding [Line Items]
Instrument Exercise Price	$ 1.35
Instrument Expiration	Sep-29
Total warrants outstanding	3,013,408	15,555,557
Warrants Outstanding Classification	Liability
Placement Agent Warrants [Member]
Schedule of Warrants Outstanding [Line Items]
Instrument Exercise Price	$ 1.69
Instrument Expiration	Sep-29
Total warrants outstanding	616,139	1,088,889
Warrants Outstanding Classification	Mezzanine equity
Common Inducement Warrants [Member]
Schedule of Warrants Outstanding [Line Items]
Instrument Exercise Price	$ 4
Instrument Expiration	Feb-30
Total warrants outstanding	2,699,797
Warrants Outstanding Classification	Liability
Placement Agent Inducement Warrants [Member]
Schedule of Warrants Outstanding [Line Items]
Instrument Exercise Price	$ 5
Instrument Expiration	Mar-30
Total warrants outstanding	188,986
Warrants Outstanding Classification	Mezzanine equity

Intangible Asset, net - Schedule of Estimated Amortization Expense (Details) $ in Thousands	Sep. 30, 2025 USD ($)
Schedule of Estimated Amortization Expense [Abstract]
FY2026	$ 1,194
FY2027	1,194
FY2028	1,194
FY2029	1,194
FY2030	1,194
Total	$ 5,970

Warrants - Schedule of Changes in Fair Value of the Liability-Classified Warrants (Details) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Schedule of Changes in Fair Value of the Liability-Classified Warrants [Line Items]
Beginning Balance	$ 6,940
Issuance	4,758	12,125
Change in fair value	34,172	(5,185)
Exercises	(26,585)
Ending Balance	19,285	6,940
Public Offering Warrants [Member]
Schedule of Changes in Fair Value of the Liability-Classified Warrants [Line Items]
Beginning Balance	6,940
Issuance		12,125
Change in fair value	30,648	(5,185)
Exercises	(26,585)
Ending Balance	11,003	6,940
Common Inducement Warrants [Member]
Schedule of Changes in Fair Value of the Liability-Classified Warrants [Line Items]
Beginning Balance
Issuance	4,758
Change in fair value	3,524
Exercises
Ending Balance	$ 8,282

Inventories (Details) $ in Thousands	12 Months Ended
Inventories (Details) $ in Thousands	Sep. 30, 2025 USD ($)
Inventories [Abstract]
Write-downs	$ 167

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024
Schedule of Inventory [Abstract]
Raw materials	$ 811				$ 619
Finished goods	313				409
Total inventories	$ 1,124	$ 1,226	$ 1,296	$ 1,216	$ 1,028

Audit Information	12 Months Ended
Audit Information	Sep. 30, 2025
Auditor [Line Items]
Auditor Name	Bush & Associates CPA LLC
Auditor Firm ID	6797
Auditor Location	Henderson, Nevada
Auditor Opinion [Text Block]	OPINION ON THE FINANCIAL STATEMENTS We have audited the accompanying consolidated balance sheets of Richtech Robotics, Inc. and Subsidiaries (the “Company”) as of September 30, 2025, and 2024, and the related consolidated statements of operations, equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2025, and 2024, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Income Taxes (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2025

^[1]

Mar. 31, 2025

^[1]

Dec. 31, 2024

^[1]

Mar. 31, 2025

^[1]

Jun. 30, 2025

^[1]

Sep. 30, 2025

Sep. 30, 2024

Income Taxes [Abstract]

Federal deferred tax benefit

$ 108

Total state tax expense

Loss before income taxes

$ (1,681)

$ (572)

$ (29,565)

$ (30,137)

$ (31,818)

$ (49,278)

$ (942)

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Warrants - Schedule of Mazzanine Equity (Details) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Schedule of Mazzanine Equity [Line Items]
Beginning Balance	$ 786
Issuance	189	786
Exercises	(341)
Remeasurement
Ending Balance	634	786
Placement Agent Warrants [Member]
Schedule of Mazzanine Equity [Line Items]
Beginning Balance	786
Issuance		786
Exercises	(341)
Remeasurement
Ending Balance	445	786
Placement Agent Inducement Warrants [Member]
Schedule of Mazzanine Equity [Line Items]
Beginning Balance
Issuance	189
Exercises
Remeasurement
Ending Balance	$ 189

Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 30
-Name Accounting Standards Codification
-Section S55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (01)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.E.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2025	Sep. 30, 2024
Class A Common Stock
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in Shares)	100,000,000	100,000,000
Common stock, shares issued (in Shares)	39,934,846	39,934,846
Common stock, shares outstanding (in Shares)	39,934,846	39,934,846
Class B Common Stock
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in Shares)	200,000,000	200,000,000
Common stock, shares issued (in Shares)	154,656,592	53,795,254
Common stock, shares outstanding (in Shares)	154,656,592	53,795,254

Accounts Receivable, Net

12 Months Ended

Sep. 30, 2025

Accounts Receivable, Net [Abstract]

Accounts Receivable, Net

NOTE 7: Accounts Receivable, Net

Accounts receivable, net of allowance for doubtful accounts, was $1,780 as of September 30, 2025, compared to $1,359 as of September 30, 2024. The 2025 balance includes gross receivables of $1,919 offset by an allowance for doubtful accounts of $139. This allowance represents management’s best estimate of potential credit losses based on the aging of customer balances and a specific identification of problematic accounts.

Subsequent Events (Details) - USD ($)					12 Months Ended
Subsequent Events (Details) - USD ($)	Jul. 31, 2026	Jan. 15, 2026	Dec. 05, 2025	Oct. 01, 2025	Sep. 30, 2025
Subsequent Event [Member]
Subsequent Events [Line Items]
Cash payment (in Dollars)			$ 32,000
Performance bonus (in Dollars)			$ 35,000
Consulting services period			12 months
Class B Common Stock [Member]
Subsequent Events [Line Items]
Company issued an aggregate class B common stock					100,861,338
Class B Common Stock [Member] \| Forecast [Member]
Subsequent Events [Line Items]
Company issued an aggregate class B common stock		19,642,631
Generating gross proceeds (in Dollars)	$ 71,622,886,310
Class B Common Stock [Member] \| Subsequent Event [Member]
Subsequent Events [Line Items]
Company issued an aggregate class B common stock				19,642,631
Generating gross proceeds (in Dollars)				$ 71,622,886,310
Restricted shares			60,000
Class B Common Stock [Member] \| Subsequent Event [Member] \| Mr. Casella [Member]
Subsequent Events [Line Items]
Restricted shares			50,000
Common Warrant [Member] \| Class B Common Stock [Member] \| Forecast [Member]
Subsequent Events [Line Items]
Exercise of warrants	4,485,946
Generating gross proceeds (in Dollars)	$ 9,813,400,080.00
Common Warrant [Member] \| Class B Common Stock [Member] \| Subsequent Event [Member]
Subsequent Events [Line Items]
Exercise of warrants				4,485,946
Generating gross proceeds (in Dollars)				$ 9,813,400,080.00
ATM Program [Member] \| Class B Common Stock [Member] \| Forecast [Member]
Subsequent Events [Line Items]
Company issued an aggregate class B common stock	15,156,685
ATM Program [Member] \| Class B Common Stock [Member] \| Subsequent Event [Member]
Subsequent Events [Line Items]
Company issued an aggregate class B common stock				15,156,685

Revenue

12 Months Ended

Sep. 30, 2025

Revenue [Abstract]

Revenue

NOTE 5: Revenue

For the fiscal year ended September 30, 2025, total net revenue was $5,045, representing a 19.0% increase over the $4,240 generated in 2024. The Company’s revenue is derived from multiple revenue streams that reflect differences in the nature of the underlying goods and services. The revenue stream was led by revenue from Robots-as-a-Service (RaaS) arrangements, which contributed $692. Product revenue from robotic sales accounted for $2,309, while leasing/service/rental arrangements generated $1,429. The remaining revenue was derived from other retail and management services $615. Revenue is recognized when control of the promised goods or services is transferred to the customer.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

Commitments and Contingencies [Abstract]

Commitments and Contingencies

12 Months Ended

Sep. 30, 2025

Commitments and contingencies

Note 14: Commitments and Contingencies

Legal Proceedings

From time to time, we may be involved in judicial or administrative proceedings concerning matters arising in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that any monetary liability or financial impact to the Company from these matters, individually and in the aggregate, would not be material to the Company’s consolidated financial position, results of operations or cash flows.

On June 2, 2025, a civil action was filed against the Company and certain of our officers in the Supreme Court of the State of New York, County of Kings (Index No. 517888/2025). The complaint asserts claims for breach of contract, breach of express and implied warranties, fraud, and joint venture liability. The plaintiff seeks damages in excess of $600,000, including compensatory and punitive damages. On September 26, 2025, we filed a motion to dismiss the case. On April 28, 2026, the parties entered into a joint stipulation adjourning oral argument on the motion to dismiss to July 15, 2026 We believe the claims are meritless and are vigorously defending the action. Based on the current stage of litigation and consultation with outside counsel, management has concluded that a loss is not probable.

Lease

We lease office facilities and retail space under noncancelable operating lease agreements. Following the purchase of the new corporate headquarters in April 2025, the existing facilities at 4175 Cameron St, Las Vegas, Nevada, continue to be leased and are now utilized for dedicated Research and Development (R&D) laboratory space and overflow administrative support. We closed our second office space in Austin, Texas, in April 2024. The total operating lease liabilities primarily relate to the Cameron Street R&D facility and the Clouffee & Tea retail space (Town Square Las Vegas). As of September 30, 2025, our operating lease liabilities were measured using a weighted average remaining lease term of approximately 2.7 years and a weighted average discount rate of approximately 4.0%.

The components of leases and lease costs are as follows (in thousands):

Operating leases	As of September 30, 2025		As of September 30, 2024
Operating lease right-of use assets	$	731	$	506
Operating lease liabilities, current portion		301		150
Operating lease liabilities, non-current portion		429		356
Total operating lease liabilities	$	730	$	506

Future minimum lease payments under these leases as of September 30, 2025, are approximately as follow:

Fiscal Year	Amount
2026	$	298
2027		307
2028		54
2029		56
2030		19
Total future minimum lease payments	$	734
Less: Imputed interest		(4	)
Present value of lease payments	$	730

Income Taxes - Schedule of Net Operating Loss Carryforward and Research Activities Credits (Details) $ / shares in Units, $ in Thousands	Sep. 30, 2025 USD ($) $ / shares
Tax Year 2023 [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss \| $	$ 219
Tax Year 2023 [Member] \| Research Activities Credit [Member]
Operating Loss Carryforwards [Line Items]
Research Activities Credit (in Dollars per share) \| $ / shares	$ 7.33
Tax Year 2024 [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss \| $	$ 6,588
Tax Year 2024 [Member] \| Research Activities Credit [Member]
Operating Loss Carryforwards [Line Items]
Research Activities Credit (in Dollars per share) \| $ / shares
Tax Year 2025 [Member]
Operating Loss Carryforwards [Line Items]
Net Operating Loss \| $	$ 10,938
Tax Year 2025 [Member] \| Research Activities Credit [Member]
Operating Loss Carryforwards [Line Items]
Research Activities Credit (in Dollars per share) \| $ / shares

Commitments and Contingencies (Tables)

12 Months Ended

Sep. 30, 2025

Commitments and Contingencies [Abstract]

Schedule of Components of Leases and Lease Costs

The components of leases and lease costs are as follows (in thousands):

Operating leases	As of September 30, 2025		As of September 30, 2024
Operating lease right-of use assets	$	731	$	506
Operating lease liabilities, current portion		301		150
Operating lease liabilities, non-current portion		429		356
Total operating lease liabilities	$	730	$	506

Schedule of Future Minimum Lease Payments

Future minimum lease payments under these leases as of September 30, 2025, are approximately as follow:

Fiscal Year	Amount
2026	$	298
2027		307
2028		54
2029		56
2030		19
Total future minimum lease payments	$	734
Less: Imputed interest		(4	)
Present value of lease payments	$	730

Earnings/Loss Per Share (Tables)

12 Months Ended

Sep. 30, 2025

Earnings/Loss Per Share [Abstract]

Schedule of Anti-Dilutive Net Loss Per Share

The following potential common stock outstanding were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive:

		September 30, 2025				September 30, 2024
Warrants to purchase Class B common stock			6,623,330				16,749,446

Schedule of Diluted Net Loss Per Share

	Year Ended September 30,
	2025			2024
Numerators:
Net loss attributable to common stockholders	$	(49,073	)	$	(1,368	)
Denominator:
Weighted Average ordinary shares used in computing		121,963,786			69,953,723
Basic and diluted net loss per share (in each dollar)	$	(0.40	)	$	(0.02	)

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) $ in Thousands	Sep. 30, 2025 USD ($)
Deferred tax assets relating to:
Net Operating loss carryforwards	$ 4,044
Research & development tax credit carryforward	7
174 Expenses	1,070
Right of Use Liability	169
Other deferred tax assets	6,843
Total gross deferred tax assets	12,133
Deferred tax liabilities relating to:
Right of Use Asset	169
Fixed Asset	18
Other deferred tax liabilities
Total Gross deferred tax liabilities	186
Deferred assets less liabilities	11,946
Less: valuation allowance	(11,946)
Net deferred tax asset (liability)

Restatement of Previously Issued Quarterly Financial Statements

12 Months Ended

Sep. 30, 2025

Restatement of Previously Issued Quarterly Financial Statements [Abstract]

Restatement of Previously Issued Quarterly Financial Statements [Text Block]

NOTE 3: Restatement of Previously Issued Quarterly Financial Statements

The errors described above, other than error ID 11, also affected the Company’s previously issued unaudited consolidated financial statements for the interim periods presented below. Accordingly, the Company has restated its previously issued unaudited consolidated financial statements for the three and nine months ended June 30, 2025, the three and six months ended March 31, 2025, and the three months ended December 31, 2024. The following tables present the impact of the restatement adjustments on the Company’s previously reported consolidated balance sheets, statements of operations, statements of cash flows, and statements of stockholders’ equity for those interim periods. The restatement corrects the identified errors in the previously issued financial statements for the Affected Periods, including the following interim-period error that did not impact the Company’s annual financial statements

12.

Stock-based compensation – The issuance of our stock based compensation awards were improperly presented within financing activities in the statement of cash flows.

13.

Issuance of shares – The issuance of shares for our intangible asset acquisition, share-based payments to employees and nonemployees, and transfers to (from) ESOP trust were recognized in incorrect interim periods.

Restated Unaudited Consolidated Balance Sheet – As of June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Inventory	$	1,482		$	(256	)		8	$	1,226
Total current assets		88,851			(256	)		*		88,595
Property and equipment, net		5,164			216			7		5,380
Intangible assets, net		11,532			(964	)		9,13		10,568
Total assets		107,329			(1,004	)		*		106,325
Warrant liability		-			7,406			2,3		7,406
Total current liabilities		739			7,406			*		8,145
Deferred income taxes		-			108			10		108
Total liabilities		1,378			7,514			*		8,892
Mezzanine equity		-			975			1		975
Additional paid-in capital		126,114			3,325			1,2,3,4,13		129,439
Retained earnings		(20,099	)		(12,818	)		*		(32,917	)
Total stockholders’ equity		105,951			(9,493	)		*		96,458
Total liabilities, mezzanine equity and stockholders’ equity	$	107,329		$	(1,004	)		*	$	106,325

Restated Unaudited Consolidated Balance Sheet – As of March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Inventory	$	1,491		$	(195	)		7,8	$	1,296
Total current assets		45,139			(195	)		*		44,944
Property and equipment, net		816			165			7		981
Intangible assets, net		9,384			1,481			9,13		10,865
Total assets		57,179			1,451			*		58,630
Warrant liability		-			7,120			2,3		7,120
Total current liabilities		596			7,120			*		7,716
Deferred income taxes		-			108			10		108
Total liabilities		1,320			7,228			*		8,548
Mezzanine equity		-			975			1		975
Additional paid-in capital		71,913			8,488			1,2,3,4,13		80,401
Retained earnings		(16,027	)		(15,240	)		*		(31,267	)
Total stockholders’ equity		55,859			(6,752	)		*		49,107
Total liabilities, mezzanine equity and stockholders’ equity	$	57,179		$	1,451			*	$	58,630

Restated Unaudited Consolidated Balance Sheet – As of December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Inventory	$	1,396		$	(180	)		7,8	$	1,216
Total current assets		39,458			(180	)		*		39,278
Property and equipment, net		802			158			7		960
Intangible assets, net		9,576			1,481			9,13		11,057
Total assets		51,424			1,459			*		52,883
Warrant liability		-			20,564			2,3		20,564
Total current liabilities		993			20,564			*		21,557
Deferred income taxes		-			108			10		108
Total liabilities		1,555			20,672			*		22,227
Mezzanine equity		-			786			1		786
Additional paid-in capital		61,366			(776	)		1,2,3,4,13		60,590
Retained earnings		(11,487	)		(19,224	)		*		(30,711	)
Total stockholders’ equity		49,869			(19,999	)		*		29,870
Total liabilities, mezzanine equity and stockholders’ equity	$	51,424		$	1,459			*	$	52,883

Restated Consolidated Statement of Operations – Three Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	301		$	445			5,8	$	746
Gross profit		876			(445	)		*		431
General and administrative		4,562			(3,153	)		5,6,7,13		1,409
Total operating expenses		5,383			(3,153	)		*		2,230
Loss from operations		(4,507	)		2,707			*		(1,800	)
Other income (loss)		-			(286	)		2,3		(286	)
Total other expenses		404			(286	)		*		118
Loss before income tax expense		(4,103	)		2,422			*		(1,681	)
Income tax benefit/(expense)		-			(9	)		*		(9	)
Consolidated net loss		(4,103	)		2,413			*		(1,690	)
Net loss attributable to common stockholders	$	(4,063	)	$	2,413			*	$	(1,650	)
Basic and diluted net loss per share of common stock	$	(0.04	)						$	(0.01	)

Restated Consolidated Statement of Operations – Nine Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	878		$	1,113			5,8	$	1,991
Gross profit		2,723			(1,113	)		*		1,610
General and administrative		13,827			(3,647	)		5,6,7,13		10,180
Total operating expenses		16,067			(3,647	)		*		12,420
Loss from operations		(13,344	)		2,534			*		(10,810	)
Other income (loss)		-			(22,123	)		2,3		(22,123	)
Total other expenses		1,115			(22,123	)		*		(21,008	)
Loss before income tax expense		(12,229	)		(19,589	)		*		(31,818	)
Consolidated net loss		(12,238	)		(19,589	)		*		(31,827	)
Net loss attributable to common stockholders	$	(12,151	)	$	(19,598	)		*	$	(31,749	)
Basic and diluted net loss per share of common stock	$	(0.11	)						$	(0.29	)

Restated Consolidated Statement of Operations – Three Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	454		$	348			5,8	$	802
Gross profit		713			(348	)		*		365
General and administrative		4,962			(205	)		5,6,7,13		4,757
Total operating expenses		5,652			(205	)		*		5,447
Loss from operations		(4,939	)		(143	)		*		(5,082	)
Other income (loss)		-			4,128			2,3		4,128
Total other expenses		382			4,128			*		4,510
Loss before income tax expense		(4,557	)		3,985			*		(572	)
Consolidated net loss		(4,557	)		3,985			*		(572	)
Net loss attributable to common stockholders	$	(4,540	)	$	3,985			*	$	(555	)
Basic and diluted net loss per share of common stock	$	(0.04	)						$	(0.00	)

Restated Consolidated Statement of Operations – Six Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	577		$	668			5,8	$	1,245
Gross profit		1,847			(668	)		*		1,179
General and administrative		9,265			(494	)		5,6,7,13		8,771
Total operating expenses		10,684			(494	)		*		10,190
Loss from operations		(8,837	)		(174	)		*		(9,011	)
Other income (loss)		-			(21,837	)		2,3		(21,837	)
Total other expenses		711			(21,837	)		*		(21,126	)
Loss before income tax expense		(8,126	)		(22,011	)		*		(30,137	)
Consolidated net loss		(8,126	)		(22,011	)		*		(30,137	)
Net loss attributable to common stockholders	$	(8,088	)	$	(22,011	)		*	$	(30,099	)
Basic and diluted net loss per share of common stock	$	(0.08	)						$	(0.29	)

Restated Consolidated Statement of Operations – Three Months Ended December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Cost of revenues	$	123		$	320			5,8	$	443
Gross profit		1,134			(320	)		*		814
General and administrative		4,303			(289	)		5,6,7,13		4,014
Total operating expenses		5,032			(289	)		*		4,743
Loss from operations		(3,898	)		(31	)		*		(3,929	)
Other income (loss)		-			(25,965	)		2		(25,965	)
Total other expenses		329			(25,965	)		*		(25,636	)
Loss before income tax expense		(3,569	)		(25,996	)		*		(29,565	)
Consolidated net loss		(3,569	)		(25,996	)		*		(29,565	)
Net loss attributable to common stockholders	$	(3,548	)	$	(25,996	)		*	$	(29,544	)
Basic and diluted net loss per share of common stock	$	(0.04	)						$	(0.31	)

Restated Consolidated Statement of Equity – Nine Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	126,114		$	3,325			*	$	129,439
Additional paid-in capital, issuance of common shares for intangible asset acquisition		5,378			(1,677	)		13		3,701
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		16,858			21,656			2,3		38,514
Additional paid-in capital, shares issued to employees		1,380			(475	)		13		905
Additional paid-in capital, shares issued for services		4,080			(1,556	)		13		2,524
Retained earnings		(20,099	)		(12,818	)		*		(32,917	)
Net loss attributable to common stockholders		(12,151	)		(19,598	)		*		(31,749	)
Total stockholders’ equity	$	105,951		$	(9,493	)		*	$	96,458

Restated Consolidated Statement of Equity – Three Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	126,114		$	3,325			*	$	129,439
Additional paid-in capital, issuance of common shares for intangible asset acquisition		2,924			(2,924	)		13		-
Additional paid-in capital, shares issued to employees		-			212			13		212
Additional paid-in capital, shares issued for services		2,591			(2,451	)		13		140
Retained earnings		(20,099	)		(12,818	)		*		(32,917	)
Net loss attributable to common stockholders		(4,063	)		2,413			*		(1,650	)
Total stockholders’ equity	$	105,951		$	(9,493	)		*	$	96,458

Restated Consolidated Statement of Equity – Six Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	71,913		$	8,488			*	$	80,401
Additional paid-in capital, issuance of common shares for intangible asset acquisition		2,454			1,247			13		3,701
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		16,858			21,656			2,3		38,514
Additional paid-in capital, shares issued to employees		867			(175	)		13		692
Additional paid-in capital, transfer to ESOP trust		513			(513	)		13		0
Additional paid-in capital, shares issued for services		1,175			1210			13		2,385
Retained earnings		(16,027	)		(15,240	)		*		(31,267	)
Net loss attributable to common stockholders		(8,088	)		(22,011	)		*		(30,099	)
Total stockholders’ equity	$	55,859		$	(6,752	)		*	$	49,107

Restated Consolidated Statement of Equity – Three Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	71,913		$	8,488			*	$	80,401
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		8,794			9,316			2,3		18,110
Additional paid-in capital, transfer to ESOP trust		513			(513	)		13		0
Additional paid-in capital, shares issued for services		1,175			283			13		1,458
Retained earnings		(16,027	)		(15,240	)		*		(31,267	)
Net loss attributable to common stockholders		(4,540	)		3,985			*		(555	)
Total stockholders’ equity	$	55,859		$	(6,752	)		*	$	49,107

Restated Consolidated Statement of Equity – Three Months Ended December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Additional paid-in capital	$	61,366		$	(776	)		2	$	60,590
Additional paid-in capital, issuance of common shares for intangible asset acquisition		2,454			1,243			13		3,697
Additional paid-in capital, issuance of shares upon exercise of warrants for cash		8,064			12,342			2		20,406
Additional paid-in capital, shares issued to employees		867			(351	)		13		516
Additional paid-in capital, shares issued for services		314			614			13		928
Retained earnings		(11,487	)		(19,224	)		*		(30,711	)
Net loss attributable to common stockholders		(3,548	)		(25,996	)		*		(29,544	)
Total stockholders’ equity	$	49,869		$	(19,999	)		*	$	29,870

Restated Consolidated Statement of Cash Flows – Nine Months Ended June 30, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Consolidated net loss	$	(12,238	)	$	(19,591	)		*	$	(31,827	)
Gain/loss on change in fair value of warrant liability		-			22,123			2,3		22,123
Issuance costs accrued related to warrants		-			189			1		189
Inventory		(334	)		331			8		(3	)
Stock-based compensation		-			3,429			12,13		3,429
Depreciation and amortization		1,635			(694	)		7,9		941
Net cash used by operating activities		(11,197	)		5,788			*		(5,409	)
Purchase of property and equipment		(4,509	)		(330	)		8		(4,839	)
Purchase of intangible assets		(100	)		16			*		(84	)
Purchase of long-term investments		(247	)		105			*		(142	)
Net cash used in investing activities		(41,532	)		(209	)		*		(41,741	)
Payment of issuance cost of ordinary shares		-			(1,180	)		12		(1,180	)
Proceeds from warrants exercise		-			18,038			12		18,038
Proceeds from issuance of ordinary shares		71,087			(22,437	)		12		48,650
Net Cash used in financing activities	$	71,056		$	(5,579	)		*	$	65,477

Restated Consolidated Statement of Cash Flows – Six Months Ended March 31, 2025

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Consolidated net loss	$	(8,126	)	$	(22,011	)		*	$	(30,137	)
Gain/loss on change in fair value of warrant liability		-			21,837			2,3		21,837
Issuance costs accrued related to warrants		-			189			1		189
Allowance for credit loss		-			(94	)		*		(94	)
Inventory		(343	)		270			8		(73	)
Stock based compensation		-			3,077			12,13		3,077
Depreciation and amortization		730			(225	)		7,9		505
Accounts receivable		(321	)		94			*		(227	)
Accrued expenses		(91	)		3			*		(88	)
Net cash used by operating activities		(8,076	)		3,139			*		(4,937	)
Purchase of property and equipment		(116	)		(270	)		8		(386	)
Net cash used by investing activities		(15,130	)		(205	)		*		(15,335	)
Payment of issuance cost of ordinary shares		0			(1180	)		12		(1180	)
Proceeds from issuance of ordinary shares		19,792			(1,754	)		12		18,038
Net cash provided by financing activities		19,766			(2,934	)		*		16,832

Restated Consolidated Statement of Cash Flows – Three Months Ended December 31, 2024

Line item	As Previously Reported on 10-Q			Restatement Adjustment			ID		As Restated
Consolidated net loss	$	(3,548	)	$	(26,017	)		*	$	(29,565	)
Gain/loss on change in fair value of warrant liability		-			25,965			2		25,965
Inventory		(248	)		60			8		(188	)
Stock based compensation		-			1,444			12,13		1,444
Depreciation and amortization		513			(232	)		7,9		281
Net cash used by operating activities		(3,578	)		1,220			*		(2,358	)
Purchase of property and equipment		(78	)		(60	)		8		(138	)
Net cash used in investing activities		(380	)		(60	)		*		(440	)
Contributions from non-controlling interests		(21	)		21			*		-
Proceeds from issuance of ordinary shares		9,244			(1,181	)		12		8,063
Net cash used in financing activities	$	9,219		$	(1,160	)		*	$	8,059

*	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Consolidated Statements of Equity - USD ($)
$ in Thousands

Common Stock

Class A

Common Stock

Class B

Additional Paid-in Capital

Accumulated Other Comprehensive Income

Retained earnings (Accumulated deficit)

NCI

Total

Balances at Sep. 30, 2023

$ 4

$ 2

$ 4,602

$ 201

$ 4,809

Balances (in Shares) at Sep. 30, 2023

44,353,846

17,813,000

Initial Public offering related expenses

(1,435)

Common stock Issuance for initial public offering

10,713

Common stock Issuance for initial public offering (in Shares)

2,142,563

Issuance of Common shares for Loan Settlement

1,300

Issuance of Common shares for Loan Settlement (in Shares)

2,294,114

Issuance of Common Shares for Intangible Asset Acquisition

$ 1

2,216

2,217

Issuance of Common Shares for Intangible Asset Acquisition (in Shares)

4,730,726

Issuance of shares upon exercise of warrants for cash

2,937

Shares Issued to Employees

Shares Issued to Employees (in Shares)

51,890

Issuance of new shares for cash (in Shares)

$ 2

14,637

14,639

22,343,961

Conversion from class A to Class B Common stock

$ 1

Conversion from class A to Class B Common stock (in Shares)

(4,419,000)

4,419,000

Balance (in Shares) at Sep. 30, 2024

(1,368)

Balance at Sep. 30, 2024

$ 4

$ 6

35,044

(1,167)

33,887

39,934,846

53,795,254

Balances at Sep. 30, 2024

^[1]

(29,565)

Balance at Dec. 31, 2024

60,590

(30,711)

^[1]

29,870

^[1]

$ 4

$ 6

35,044

(1,167)

33,887

Balances (in Shares) at Sep. 30, 2024

39,934,846

53,795,254

Balances at Sep. 30, 2024

^[1]

(30,137)

Balance at Mar. 31, 2025

^[1]

80,401

(31,267)

49,107

$ 4

$ 6

35,044

(1,167)

33,887

Balances (in Shares) at Sep. 30, 2024

39,934,846

53,795,254

Balances at Sep. 30, 2024

^[1]

(31,827)

Balance at Jun. 30, 2025

^[1]

129,439

(32,917)

96,458

$ 4

$ 6

35,044

(1,167)

33,887

Balances (in Shares) at Sep. 30, 2024

39,934,846

53,795,254

Issuance of Common Shares for Intangible Asset Acquisition

$ 1

3,701

3,702

Issuance of Common Shares for Intangible Asset Acquisition (in Shares)

5,788,849

Issuance of shares upon exercise of warrants for cash

$ 1

38,433

38,434

Issuance of shares upon exercise of warrants for cash (in Shares)

13,014,899

Shares Issued to Employees

$ 0

1,089

Shares Issued to Employees (in Shares)

1,023,040

Issuance of new shares for cash (in Shares)

$ 8

219,799

219,807

79,241,455

Shares Issued for services

2,635

Shares Issued for services (in Shares)

1,793,095

Net Loss attributable to NCI

(108)

Capital Contribution from NCI

Other Comprehensive Income

393

Balance (in Shares) at Sep. 30, 2025

(49,074)

Balance at Sep. 30, 2025

$ 4

$ 16

300,701

$ 393

(50,241)

$ (43)

250,830

39,934,846

154,656,592

Balances at Dec. 31, 2024

60,590

(30,711)

^[1]

29,870

^[1]

^[1]

(572)

Balance at Mar. 31, 2025

^[1]

$ 80,401

$ (31,267)

$ 49,107

[1]	Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.

Consolidated statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Statement of Comprehensive Income [Abstract]
Net loss attributable to common stockholders	$ (49,074)	$ (1,368)
Other comprehensive income:
Unrealized net gain on investments, net of tax	393
Comprehensive loss	$ (48,681)	$ (1,368)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Summary of Significant Accounting Policies [Abstract]

Commitments and Contingencies - Schedule of Components of Leases and Lease Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Schedule of Leases and Lease Costs [Abstract]
Operating lease right-of use assets	$ 731	$ 506
Operating lease liabilities, current portion	301	150
Operating lease liabilities, non-current portion	429	356
Total operating lease liabilities	$ 730	$ 506

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Current assets:
Cash and cash equivalents	$ 185,574	$ 14,566
Short term investment	66,363	15,940
Accounts receivable, (net of allowance for doubtful accounts)	1,780	1,359
Inventory	1,124	1,028
Prepaid expenses and other current assets	429	33
Total current assets	255,270	32,926
Property and equipment, net	5,794	842
Notes receivable	523
Operating lease right-of-use-assets	731	506
Intangible assets, net	10,715	7,620
Other assets, non-current	640	740
Total assets	273,673	42,634
Current liabilities:
Accounts payable	397	150
Deferred revenue	248
Accrued expenses and other payables	1,376	97
Short-term loan		53
Tax payables	55	5
Operating lease liabilities, current	301	150
Warrant liabilities	19,285	6,940
Total current liabilities	21,662	7,395
Deferred income taxes		108
Long-term payables	118	102
Operating lease liabilities, non-current	429	356
Total liabilities	22,209	7,961
Commitments and contingencies (Note 14)
Mezzanine equity	634	786
Stockholders’ equity:
Additional Paid-in Capital	300,701	35,044
Accumulated other comprehensive income	393
Accumulated deficit	(50,241)	(1,167)
Total controlling stockholders’ equity	250,873	33,887
Non-controlling interests	(43)
Total stockholder’s equity	250,830	33,887
Total liabilities, mezzanine equity and stockholder’s equity	273,673	42,634
Class A Common Stock
Stockholders’ equity:
Common stock, value	4	4
Class B Common Stock
Stockholders’ equity:
Common stock, value	$ 16	$ 6

Accounting Policies, by Policy (Policies)

12 Months Ended

Sep. 30, 2025

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Segment Reporting

Segment Reporting

Cash and Cash Equivalents

Cash and Cash Equivalents

Investments

Investments

Warrants

Warrants

For equity-classified warrants, fair value is measured at issuance with no subsequent remeasurement.

Standby Equity Purchase Agreements

Standby Equity Purchase Agreement

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Property, and Equipment, net

Property, and Equipment, net

Property and equipment, as of September 30, 2025 and 2024 are as follows:

	Years Ended September 30,
	2025			2024
Furniture, fixtures & equipment	$	1,435		$	789
Equipment held for lease		536			120
Leasehold improvements		4			4
Building		2,973			-
Land		1,109			-
		6,057			913
Accumulated depreciation		(263	)		(71	)
Property and equipment, net	$	5,794		$	842

Depreciation expenses for 2025 and 2024 were $192 and $31, respectively.

Rights and Privileges of Common Stock

Rights and Privileges of Common Stock

Listing on Nasdaq

On November 17, 2023, the Company’s shares of Class B common stock commenced trading on the Nasdaq Capital Market under the ticker symbol “RR.”

Mezzanine Equity

Mezzanine Equity

Revenue Recognition

Revenue Recognition

Product Revenue

Revenue from Robots-as-a-Service (RaaS)

Revenue from Leasing

Remaining Performance Obligations

Contract assets and contract liabilities

We maintain contract-related balance sheet accounts under ASC 606, Revenue from Contracts with Customers, which primarily arise from Robotics-as-a-Service (RaaS) arrangements.

No contract balances are attributable to leasing activities, as the Company did not generate revenue from lease arrangements during fiscal year 2025.

Other Revenue Policies

Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

We account for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products.

We record the related costs within cost of goods sold.

Research and Development Costs

Research and Development Costs

Income Taxes

Income Taxes

The Company recognizes interest and penalties on income taxes as a component of income tax expense.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Sep. 30, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Income Taxes

12 Months Ended

Sep. 30, 2025

Income Taxes [Abstract]

Income Taxes

NOTE 10: Income Taxes

The Company’s financial statements include a total federal deferred tax benefit of $108 and state tax expense of $2 on a loss before income taxes of approximately $49 for the years ended September 30, 2025. A reconciliation of the difference between the (expense)/benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands, except amounts pertaining to rate which are shown as a percentage):

	Years Ended September 30, 2025
Federal Statutory Rate		21.00	%
Effect of:
Change in Valuation Allowance		(22.94	)%
RTP & Deferred True-up		(0.01	)%
Change in Rate		0.07	%
State Tax Benefit (Net of Fed)		1.90	%
M&E		(0.03	)%
Liability instrument issuance costs		(0.08	)%
Others		0.31	%
Total provision effective rate		0.22	%

The components of deferred tax assets and liabilities are as follows (in thousands):

	September 30, 2025
Deferred tax assets relating to:
Net Operating loss carryforwards	$	4,044
Research & development tax credit carryforward		7
174 Expenses		1,070
Right of Use Liability		169
Other deferred tax assets		6,843
Total gross deferred tax assets		12,133
Deferred tax liabilities relating to:
Right of Use Asset		169
Fixed Asset		18
Other deferred tax liabilities		-
Total Gross deferred tax liabilities		186
Deferred assets less liabilities		11,946
Less: valuation allowance		(11,946	)
Net deferred tax asset (liability)	$	-

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income (losses) and projections for future taxable income (losses) over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that the Company will not realize the benefits of these deductible differences in the future. The Company had the following federal net operating loss carryforward and research activities credits as of September 30, 2025 (in thousands):

Year incurred	Net Operating Loss		Research Activities Credit
2023	$	219		7.33
2024		6,588		-
2025		10,938

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Cybersecurity Risk Management and Strategy Disclosure

12 Months Ended

Sep. 30, 2025

Cybersecurity Risk Role of Management [Text Block]

Cybersecurity Risk Management and Strategy

Our Company has a dedicated internal IT specialists with cybersecurity engineers who oversee various aspects of cybersecurity. These engineers specialize in different areas, including ensuring security during product development, particularly in the domains of cloud management platforms and network interactions, as well as managing cybersecurity for daily office communications.

In the event of an unexpected cybersecurity incident, the engineers immediately report to the Company’s management. They are equipped with pre-established response plans to address such situations effectively and mitigate potential risks.

Currently, our cybersecurity risk management relies primarily on internal resources. However, as the Company continues to expand, we anticipate engaging third-party consultants to assist in enhancing our cybersecurity management processes and addressing evolving threats.

While we do not currently have third-party collaborations, the Company plans to implement a process for selecting and evaluating third-party service providers in the future. This will include comparing services, signing security agreements, and having our internal engineers assess the third parties’ achievement of security objectives.

In the past three years, our Company has not experienced any material cybersecurity risks. To ensure robust protection against potential threats, we have implemented the following security measures:

●

Regularly updating and changing critical passwords.

●

Periodically modifying communication interfaces to enhance security.

●

Assigning development tasks in a modular fashion to minimize exposure.

●

Utilizing dual-factor authentication for system access.

●

Implementing tiered authorization levels for critical network operations.

●

Conducting routine security training and awareness programs for employees.

Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]

false

Cybersecurity Risk Management Third Party Engaged [Flag]

false

Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]

In the past three years, our Company has not experienced any material cybersecurity risks. To ensure robust protection against potential threats, we have implemented the following security measures:

●

Regularly updating and changing critical passwords.

●

Periodically modifying communication interfaces to enhance security.

●

Assigning development tasks in a modular fashion to minimize exposure.

●

Utilizing dual-factor authentication for system access.

●

Implementing tiered authorization levels for critical network operations.

●

Conducting routine security training and awareness programs for employees.

Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]

true

Cybersecurity Risk Board of Directors Oversight [Text Block]

Cybersecurity Governance

Currently, the Company’s board of directors does not oversee cybersecurity risks directly. However, plans are in place to introduce such oversight in the future. The Audit Committee of the Board will assume responsibility for cybersecurity risk oversight, with a plan to review cybersecurity matters on a quarterly basis. This initiative will ensure that the Company maintains robust oversight mechanisms to address evolving cybersecurity threats effectively.

The responsibility for assessing and managing cybersecurity risks within the Company lies with the managers of the R&D department and the IT specialists. Both individuals possess relevant expertise in their respective fields, ensuring a high level of competence in identifying and mitigating cybersecurity risks. Their duties include monitoring potential threats, implementing security protocols, and responding to incidents to safeguard company assets and operations.

In the event of cybersecurity incidents or abnormal alerts, the relevant department managers immediately intervene and manage the situation. All logs and records related to such events are preserved for future analysis. Cybersecurity testing is incorporated into every stage of product development, ensuring that vulnerabilities are identified and addressed proactively. Additionally, server security patches are regularly updated to mitigate potential threats.

Cybersecurity Risk Management Positions or Committees Responsible [Text Block]

Cybersecurity Risk Management Positions or Committees Responsible [Flag]

true

Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]

The Audit Committee of the Board will assume responsibility for cybersecurity risk oversight, with a plan to review cybersecurity matters on a quarterly basis.

Cybersecurity Risk Management Expertise of Management Responsible [Text Block]

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Revenue, net	$ 5,045	$ 4,240
Cost of revenue, net	3,235	1,537
Gross profit	1,810	2,703
Operating expenses:
Research and development	3,302	2,635
Sales and marketing	741	1,315
General and administrative	14,967	6,533
Total operating expenses	19,010	10,483
Income (loss) from operations	(17,200)	(7,780)
Non-operating income(expense):
Investment income	2,177	13
Other income (loss)	(34,172)	7,587
Interest expense, net	(83)	(762)
Total other expense	(32,078)	6,838
Loss before income tax expense	(49,278)	(942)
Income tax benefit / (expense)	96	(426)
Consolidated net loss	(49,182)	(1,368)
Less: Net loss Attributable to Non-Controlling Interest	(108)
Net loss attributable to common stockholders	$ (49,074)	$ (1,368)
Basic net loss per share of common stock (in Dollars per share)	$ (0.4)	$ (0.02)
Diluted net loss per share of common stock (in Dollars per share)	$ (0.4)	$ (0.02)
Weighted average shares used to compute basic net loss per share (in Shares)	121,963,786	69,953,723
Weighted average shares used to compute diluted net loss per share (in Shares)	121,963,786	69,953,723

Inventories (Tables)

12 Months Ended

Sep. 30, 2025

Inventories [Abstract]

Schedule of Inventory

Inventory as of September 30, 2025 and 2024 are as follows:

	Year Ended September 30,
	2025		2024
Raw materials	$	811	$	619
Finished goods		313		409
Total inventories	$	1,124	$	1,028

Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Sep. 30, 2025 USD ($)
Commitments and Contingencies [Abstract]
Plaintiff seeks damages	$ 600,000
Weighted average remaining lease term	2 years 8 months 12 days
Weighted average discount rate	4.00%

Earnings/Loss Per Share - Schedule of Anti-Dilutive Net Loss Per Share (Details) - shares	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Class B Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants to purchase Class B common stock	6,623,330	16,749,446

Warrants - Schedule of Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Schedule of Valuation Assumptions [Line Items]
Exercise price		$ 1.35
Expected term (in years)		4 years 11 months 4 days
Volatility		74.90%
Risk-free interest rate		3.55%
Public Offering Warrants [Member]
Schedule of Valuation Assumptions [Line Items]
Share Price	$ 1.27
Exercise price	$ 1.35
Expected term (in years)	5 years
Volatility	73.60%
Risk-free interest rate	3.62%
Common Inducement Warrants [Member]
Schedule of Valuation Assumptions [Line Items]
Share Price	$ 3.01
Exercise price	$ 4
Expected term (in years)	5 years
Volatility	75.20%
Risk-free interest rate	4.29%
Warrant [Member]
Schedule of Valuation Assumptions [Line Items]
Share Price	$ 4.29	$ 0.84
Warrant [Member] \| Maximum [Member]
Schedule of Valuation Assumptions [Line Items]
Exercise price	$ 4
Expected term (in years)	4 years 4 months 9 days
Volatility	100.80%
Risk-free interest rate	3.66%
Warrant [Member] \| Minimum [Member]
Schedule of Valuation Assumptions [Line Items]
Exercise price	$ 1.35
Expected term (in years)	3 years 11 months 4 days
Volatility	95.10%
Risk-free interest rate	3.64%
Placement Agent Warrants [Member]
Schedule of Valuation Assumptions [Line Items]
Share Price	$ 1.27
Exercise price	$ 1.69
Expected term (in years)	5 years
Volatility	73.60%
Risk-free interest rate	3.62%
Placement Agent Inducement Warrants [Member]
Schedule of Valuation Assumptions [Line Items]
Share Price	$ 1.98
Exercise price	$ 5
Expected term (in years)	4 years 11 months 12 days
Volatility	82.70%
Risk-free interest rate	3.92%

Stockholders' Equity

12 Months Ended

Sep. 30, 2025

Stockholders’ Equity [Abstract]

Stockholders' Equity

Note 13: Stockholders’ Equity

As of September 30, 2025, the Company had 39,934,846 shares of Class A common stock and 154,656,592 shares of Class B common stock issued and outstanding. As of September 30, 2024, the Company had 39,934,846 shares of Class A common stock and 53,795,254 shares of Class B common stock issued and outstanding. During the fiscal year ended September 30, 2025, the Company issued an aggregate of 100,861,338 shares of Class B common stock and no additional shares of Class A common stock. The material issuances of the Company’s Class B common stock are described below.

On November 21, 2023, the Company issued an aggregate of 2,100,000 shares of Class B common stock at a price of $5.00 per share in connection with the closing of its initial public offering (“IPO”). On December 22, 2023, the Company issued an additional 42,563 shares of Class B common stock at a price of $5.00 per share pursuant to the partial exercise of the underwriters’ over-allotment option. In connection with the IPO, the Company also issued warrants to the representative of the offering to purchase shares of common stock (the “Representative’s Warrants”). The Representative’s Warrants were issued as consideration for underwriting services, are accounted for as share-based payment awards, and are classified in permanent equity.

On February 15, 2024, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”), pursuant to which Yorkville agreed to purchase up to $50 million of the Company’s Class B common stock over a 24-month period. The purchase price for shares issued under the SEPA is equal to 96% of the lowest volume weighted average price (“VWAP”) of the Company’s Class B common stock during the three trading days immediately following delivery of an advance notice by the Company. Each issuance and sale under the SEPA (an “Advance”) is subject to a maximum amount equal to 100% of the daily trading volume of the Company’s Class B common stock, as reported by Bloomberg L.P., during the five trading days immediately preceding an Advance notice. On April 22, 2024, the Company issued 259,350 commitment shares to Yorkville pursuant to the SEPA. As of September 30, 2024, the Company had issued an aggregate of 8,776,211 shares of Class B common stock under the SEPA. For a more detailed description of the SEPA, refer to the Company’s Current Report on Form 8-K/A filed with the SEC on March 15, 2024. For the year ended September 30, 2025, the Company did not recognize any losses related to issuances under the SEPA. For the year ended September 30, 2024, the Company recognized losses related to issuances under the SEPA of $2,305, which were recorded within other income (loss).

On September 3, 2024, the Company completed a public offering pursuant to a Securities Purchase Agreement, dated August 29, 2024, with certain institutional investors and a prospectus dated August 29, 2024, filed with the SEC on August 30, 2024, relating to certain retail purchasers (collectively, the “Investors”). In connection with the offering, the Company issued (i) 13,242,963 shares of Class B common stock, (ii) pre-funded warrants to purchase up to 2,312,594 shares of Class B common stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 15,555,557 shares of Class B common stock (the “Common Warrants”), at a purchase price of $1.35 per share and accompanying Common Warrant. The Pre-Funded Warrants were immediately exercisable at an exercise price of $0.00001 per share and remain exercisable until exercised in full. The Common Warrants were immediately exercisable at an exercise price of $1.35 per share and expire five years from the date of issuance.

As of September 30, 2024, the Company had issued an aggregate of 2,312,594 shares of Class B common stock pursuant to the exercise of all of the outstanding Pre-Funded Warrants in full, at an exercise price of $0.00001 per share. As of September 30, 2024, the Company issued zero shares of Class B common stock pursuant to the exercise of Common Warrants, at an exercise price of $1.35 per share.

During the fiscal year ended September 30, 2024, the Company issued an aggregate of 4,829,573 shares of Class B common stock under the Amended and Restated Richtech Robotics, Inc. 2023 Stock Option Plan, consisting of the following: (i) 4,730,726 shares of Class B common stock issued to consultants as compensation for technology development services. Upon completion of the development, the resulting technology was recognized as an intangible asset on the Company’s balance sheet in accordance with ASC 350 and ASC 718; (ii) 51,890 shares of Class B common stock issued as stock compensation to employees and directors; and (iii) 46,957 shares of Class B common stock allocated to the employee and director equity incentive pool.

During the fiscal year ended September 30, 2024, the Company issued an aggregate of 4,419,000 shares of Class B common stock to stockholders upon the conversion of an equal number of shares of Class A common stock.

During the fiscal year ended September 30, 2025, the Company issued an aggregate of 79,241,455 shares through at-the-market (“ATM”) offerings.

During the fiscal year ended September 30, 2025, the Company issued 8,721,735 shares of Class B common stock under the Amended and Restated Richtech Robotics, Inc. 2023 Stock Option Plan, consisting of the following: (i) 5,788,849 shares of Class B common stock issued to consultants as compensation for technology development services. Upon completion of the development, the resulting technology was recognized as an intangible asset on the Company’s balance sheet in accordance with ASC 350 and ASC 718; (ii) 1,023,040 shares of Class B common stock issued as stock compensation to employees; and (iii) 1,793,095 shares of Class B common stock issued for legal and professional services. 861,904 shares of Class B common stock remained available under the employee and director equity incentive pool.

During the fiscal year ended September 30, 2025, the Company issued an aggregate of 13,014,899 shares of Class B common stock pursuant to the exercise of investor warrants.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18